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A B S T R A C T
Background
Retinitis pigmentosa (RP) comprises a group of hereditary eye diseases characterized by progressive degeneration of retinal
photoreceptors. It results in severe visual loss that may lead to blindness. Symptoms may become manifest during childhood or adulthood
which include poor night vision (nyctalopia) and constriction of peripheral vision (visual field loss). Visual field loss is progressive and aCects
central vision later in the disease course. The worldwide prevalence of RP is approximately 1 in 4000, with 100,000 individuals aCected in
the USA. At this time, there is no proven therapy for RP.
Objectives
The objective of this review was to synthesize the best available evidence regarding the eCectiveness and safety of vitamin A and fish oils
(docosahexaenoic acid (DHA)) in preventing the progression of RP.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), which contains the Cochrane Eyes and Vision Trials Register
(2020, Issue 2); Ovid MEDLINE; Embase.com; PubMed; Latin American and Caribbean Health Sciences Literature Database (LILACS);
ClinicalTrials.gov; the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP); and OpenGrey. We did not
use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 7 February 2020.
Selection criteria
We included randomized controlled trials that enrolled participants of any age diagnosed with any degree of severity or type of RP, and
evaluated the eCectiveness of vitamin A, fish oils (DHA), or both compared to placebo, vitamins (other than vitamin A), or no therapy, as a
treatment for RP. We excluded cluster-randomized trials and cross-over trials.
Data collection and analysis
We prespecified the following outcomes: mean change from baseline visual field, mean change from baseline electroretinogram (ERG)
amplitudes, and anatomic changes as measured by optical coherence tomography (OCT), at one-year follow-up, and mean change in visual
acuity, at five-year follow-up. Two review authors independently extracted data and evaluated risk of bias for all included trials. We also
contacted study investigators for further information when necessary.
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa (Review)









Cochrane Database of Systematic Reviews
Main results
In addition to three trials from the previous version of this review, we included a total of four trials with 944 participants aged 4 to 55 years.
Two trials included only participants with X-linked RP and the other two included participants with RP of all forms of genetic predisposition.
Two trials evaluated the eCect of DHA alone; one trial evaluated vitamin A alone; and one trial evaluated DHA and vitamin A versus vitamin
A alone. Two trials recruited participants from the USA, and the other two recruited from the USA and Canada. All trials were at low risk of
bias for most domains. We did not perform meta-analysis due to clinical heterogeneity.
Four trials assessed visual field sensitivity. Investigators found no evidence of a diCerence in mean values between the groups. However,
one trial found that the annual rate of change of visual field sensitivity over four years favored the DHA group in foveal (−0.02 ± 0.55 (standard
error (SE)) dB versus −0.47 ± 0.03 dB, P = 0.039), macular (−0.42 ± 0.05 dB versus −0.85 ± 0.03 dB, P = 0.031), peripheral (−0.39 ± 0.02 versus
−0.86 ± 0.02 dB, P < 0.001), and total visual field sensitivity (−0.39 ± 0.02 versus −0.86 ± 0.02 dB, P < 0.001). The certainty of the evidence
was very low.
The four trials evaluated visual acuity (LogMAR scale) at a follow-up of four to six years. In one trial (208 participants), investigators found
no evidence of a diCerence between the two groups, as both groups lost 0.7 letters of the Early Treatment Diabetic Retinopathy Study
(ETDRS) visual acuity per year. In another trial (41 participants), DHA showed no evidence of eCect on visual acuity (mean diCerence −0.01
logMAR units (95% confidence interval −0.14 to 0.12; one letter diCerence between the two groups; very low-certainty evidence). In the
third trial (60 participants), annual change in mean number of letters correct was −0.8 (DHA) and 1.4 letters (placebo), with no evidence
of between-group diCerence. In the fourth trial (572 participants), which evaluated (vitamin A + vitamin E trace) compared with (vitamin A
trace + vitamin E trace), decline in ETDRS visual acuity was 1.1 versus 0.9 letters per year, respectively.
All four trials reported electroretinography (ERG). Investigators of two trials found no evidence of a diCerence between the DHA and placebo
group in yearly rates of change in 31 Hz cone ERG amplitude (mean ± SE) (−0.028 ± 0.001 log μV versus −0.022 ± 0.002 log μV; P = 0.30); rod
ERG amplitude (mean ± SE) (−0.010 ± 0.001 log μV versus −0.023 ± 0.001 log μV; P = 0.27); and maximal ERG amplitude (mean ± SE) (−0.042 ±
0.001 log μV versus −0.036 ± 0.001 log μV; P = 0.65). In another trial, a slight diCerence (6.1% versus 7.1%) in decline of ERG per year favored
vitamin A (P = 0.01). The certainty of the evidence was very low.
One trial (51 participants) that assessed optical coherence tomography found no evidence of a diCerence in ellipsoid zone constriction (P
= 0.87) over two years, with very low-certainty evidence. The other three trials did not report this outcome.
Only one trial reported adverse events, which found that 27/60 participants experienced 42 treatment-related emergent adverse events
(22 in DHA group, 20 in placebo group). The certainty of evidence was very low. The rest of the trials reported no adverse events, and no
study reported any evidence of benefit of vitamin supplementation on the progression of visual acuity loss.
Authors' conclusions
Based on the results of four studies, it is uncertain if there is a benefit of treatment with vitamin A or DHA, or both for people with RP.
Future trials should also take into account the changes observed in ERG amplitudes and other outcome measures from trials included in
this review.
P L A I N   L A N G U A G E   S U M M A R Y
Use of vitamin A and fish oils for retinitis pigmentosa
What is the aim of this review?
The aim of this Cochrane Review was to determine whether vitamin A and fish oils work in delaying the continued worsening of vision in
people with an inherited condition of the eyes that causes loss of vision (retinitis pigmentosa) and whether these treatments are safe.
Key messages
We are uncertain whether giving vitamin A or fish oil, or both to people with retinitis pigmentosa delays the continued worsening of vision,
as the certainty of the evidence was very low. More research is needed, in particular information about whether vitamin A and/or fish oil
with or without other vitamin supplements may aCect clinical outcomes.
What was studied in the review?
Retinitis pigmentosa is a group of inherited eye disorders that cause a gradual, yet progressive, loss of vision. People with this eye disorder
have diCiculty seeing in low-light conditions, problems with vision out of the corner of the eye, and in most cases, gradually become visually
impaired. Vitamin A or fish oils, or both have been proposed as having possible benefit in helping delay the progression of vision loss in
this group of people.
What are the main results of the review?
We found four studies that were conducted in the USA and Canada, including a total of 944 participants between the ages of 4 and 55 years.
The participants were given vitamin A or fish oil, or both because of their inherited eye disorder and were followed for four years. People
who were given vitamin A or fish oil, or both, were compared with those who were not given vitamin A or fish oil. Participants in the vitamin
A and/or fish oil group were given diCerent doses of vitamin A or fish oil for diCering lengths of time. Participants in the no-vitamin A and/
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa (Review)
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or fish oil group were given pills that did not include vitamin A or fish oil (placebo pills); other treatments thought to prevent progression
of vision loss such as multivitamins with or without traces of vitamin A; or no treatment at all.
The review shows that whether vitamin A or fish oil, or both, makes any diCerence in delaying the progression of visual loss is uncertain.
How up-to-date is this review?
We searched for studies that had been published up to 7 February 2020.
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa (Review)



















































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Vitamin A and fish oils (docosahexaenoic acid) compared to placebo, vitamins (including vitamin A), or no therapy for
retinitis pigmentosa
Vitamin A and fish oils (docosahexaenoic acid) compared to placebo, vitamins (including vitamin A), or no therapy for retinitis pigmentosa
Patient or population: retinitis pigmentosa
Setting: eye hospital
Intervention: vitamin A and fish oils (docosahexaenoic acid)
Comparison: placebo, vitamins (including vitamin A), or no therapy
Anticipated absolute effects* (95% CI)Outcomes
Risk with placebo, vita-
mins (including vitamin
A), or no therapy













sured in decibels (dB)
follow-up: range 4
years to 6 years
Investigators in all 4 trials found no difference in mean values between DHA and placebo groups. However, in 1
trial, the annual rate of change over 4 years showed benefit in favor of the DHA group compared to the placebo
group in foveal (−0.02 ± 0.55 (standard error) dB versus −0.47 ± 0.03 dB, P = 0.039), macular (−0.42 ± 0.05 dB versus
−0.85 ± 0.03 dB, P = 0.031), peripheral (−0.39 ± 0.02 versus −0.86 ± 0.02 dB, P < 0.001), and total visual field sensitivi-







change in logMAR vi-
sual acuity, may be re-
ported as ETDRS
follow-up: range 4
years to 6 years
In 1 trial (208 participants), investigators found no difference between the 2 groups, as both groups lost 0.7 letters
of ETDRS visual acuity per year.
In another trial (41 participants), when compared to placebo, DHA showed no effect on change from baseline visu-
al acuity (mean difference −0.01 logMAR units, 95% CI −0.14 to 0.12), representing less than 1 letter difference be-
tween the 2 groups.
Data from investigators of the third study (60 participants) found that annual change in mean number of letters
correct was −0.8 in DHA group and 1.4 letters in placebo group, with no between-group difference observed.
The fourth trial (572 participants) compared (vitamin A + vitamin E trace) to (vitamin A trace + vitamin E trace) and
found that decline in ETDRS visual acuity was 1.1 letters per year in the (vitamin A + vitamin E trace) group and 0.9










mean change in ERG
amplitude (rod re-
All 4 trials examined the treatment effect associated with DHA on ERG amplitudes, and 1 trial examined the effect
of vitamin A on ERG. 1 study reported that the vitamin A group had, on average, a slower rate of decline of retinal
function than the group not receiving this dosage. In a post hoc analysis in another trial, investigators observed an
8.3% decline in ERG per year in the vitamin A group versus 10% decline per year in non-vitamin A group; P < 0.001,



















































































































































sponse, and cone re-
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follow-up: 4 years
ipants in this trial, the decline in ERG was 6.1% per year in vitamin A group versus 7.1% per year in non-vitamin A













Adverse effects: as re-
ported by studies
1 trial reported that 27/60 participants experienced 42 treatment-related emergent adverse events (22 in DHA






*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; DHA: docosahexaenoic acid; ETDRS: Early Treatment Diabetic Retinopathy Study; RCT: randomized controlled trial
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
1Downgraded one level for risk of bias, due to potential attrition and reporting bias.
2Downgraded one level for inconsistency, due to clinical heterogeneity.




































































Cochrane Database of Systematic Reviews
B A C K G R O U N D
Description of the condition
The term 'retinitis pigmentosa' (RP) comprises a diverse group
of diseases characterized by progressive degeneration of the
retinal photoreceptors (light-sensing cells) and the adjacent retinal
pigment epithelium. RP may occur as part of a syndrome, including
abnormalities of other organs, or in a non-syndromic form in which
the clinical manifestations are restricted to the eye (65% of all
cases in the USA) (Daiger 2007). RP is oSen associated with other
ocular abnormalities in addition to retinal degeneration, such as
cataract (clouding of the lens of the eye) or cystoid macular edema
(swelling of the central retina). The worldwide prevalence of RP is
approximately 1 in 4000, with 100,000 people aCected in the USA
(Hartong 2006).
RP is a genetic condition, and its inheritance pattern may be
autosomal dominant (30%), autosomal recessive (20%), X-linked
(15%), mitochondrial (5%), or sporadic (30%). At least 50 separate
gene defects have been reported to be associated with RP (Daiger
2007).
Depending on the specific genetic variant, symptoms may manifest
during childhood or adulthood. The initial symptoms are typically
poor night vision (nyctalopia) and constriction of peripheral vision
(visual field loss). This field loss is progressive, and usually central
vision is not reduced until late in the disease course.
The natural course of RP involves an approximate 4% to 12% annual
loss of visual field (Berson 1985). In addition to the visual field loss,
deterioration of visual acuity and full-field electroretinogram (ERG)
changes are observed. Visual acuity loss occurs more gradually
compared to visual field loss and is more severe if the central retina
(macula) is aCected (Flynn 2001; Holopigian 1996). On average, a
decline in visual acuity of one line is observed over five years for
individuals without macular lesions, compared to a loss of three to
four lines in those with macular involvement (Flynn 2001).
The diagnosis of RP is made on clinical examination. Typical
findings include abnormal pigmented changes in the peripheral
retina (known as bone spicules, because of their similarity to the
microscopic appearance of bone), pallor (paleness) of the optic
disc (or optic nerve head, part of the optic nerve), and attenuation
(narrowing) of the retinal blood vessels. Cataract and cystoid
macular edema may also be noted.
Peripheral vision is measured with visual field testing, frequently
with a static Humphrey perimeter (automated threshold perimeter)
or kinetic Goldmann perimeter. Full-field ERG provides additional
quantitative measurement of disease progression. RP patients
have reduced rod (elicited by dark-adapted flash) and cone (elicited
by single flash) response amplitudes and a delay in timing from
stimulus to peak rod- or cone-isolated responses (Berson 1969). It
has been estimated that people with RP lose approximately 17% of
remaining ERG amplitude per year (Berson 1985). Changes in the
ERG are generally observed before clinical detection of changes in
visual field and visual acuity.
Studies have documented microscopic changes in the retinal
layers using a newer, non-invasive clinical test known as optical
coherence tomography (OCT) (Walia 2007; Witkin 2006). Witkin 2006
reported that the foveal photoreceptor outer segment/pigment
epithelial thickness was significantly lower in eyes with RP than in
controls. Oishi 2009 correlated findings from OCT with changes in
visual acuity: patients without integrity of the inner segment-outer
segment junction of the photoreceptors had greater loss of visual
acuity than patients with a more normal tomographic appearance.
Description of the intervention
Certain ophthalmic conditions associated with RP can be treated
successfully. For example, cataract surgery may be performed
for RP-associated cataract, and various medications may be
eCective in the treatment of RP-associated cystoid macular edema.
However, there is no proven treatment that slows or delays the
progressive retinal degeneration.
Treatments that have been studied include oral supplementation
with vitamin A (retinyl palmitate), the omega-3 long-chain
polyunsaturated fatty acid docosahexaenoic acid (DHA), or both
(Birch 2005; Hodge 2005).
How the intervention might work
Mechanisms through which vitamin A and DHA might modify the
disease process in RP have not yet been fully explained. However,
vitamin A has been reported to have an important role in the
function of retinal photoreceptors (Berson 1982; Dowling 1960).
Rhodopsin is a pigment located in retinal rods that allows the
rods to detect small amounts of light. Rhodopsin, along with other
pigments in the retina, stores vitamin A compounds; vitamin A is
important for rhodopsin formation and the visual cycle.
Similarly, DHA is found within photoreceptor cell membranes, and
some authors have suggested that it has a functional role (Chen
1996).
Why it is important to do this review
RP is an uncommon but clinically important disease. It is
progressive, potentially blinding, and has no proven treatment.
Vitamin A and fish oils have been proposed as having some
therapeutic potential in some of the clinical trials conducted. The
most recent version of this review was published seven years
ago (Rayapudi 2013), thus an update was needed to evaluate
both earlier and more recent evidence on the relative safety and
eCectiveness of vitamin A and fish oils (DHA) in preventing the
progression of RP.
O B J E C T I V E S
The objective of this review was to synthesize the best available
evidence regarding the eCectiveness and safety of vitamin A
and fish oils (docosahexaenoic acid (DHA)) in preventing the
progression of RP.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomized controlled trials (RCTs) of any design,
including parallel and factorial. We did not include cross-over trials
or cluster-randomized trials, as these designs could not address our
question of interest.
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa (Review)
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We excluded studies that used quasi-random allocation methods
such as alternation, case-record numbers, dates of birth, or days
of the week for randomizing participants to a group. Although
trials with quasi-random allocation methods may provide data that
support findings from RCTs, they are susceptible to selection bias
and confounding.
Types of participants
We included trials that enrolled participants of any age diagnosed
with any degree of severity or type of RP. If trials included
participants with varying severity or stage of disease, we extracted
baseline characteristics to explore disease severity as a source of
variability across trials (see Subgroup analysis and investigation of
heterogeneity).
Types of interventions
We included trials evaluating the eCectiveness of vitamin A
(administered as vitamin A1, retinyl palmitate, 11-cis retinol,
retinol, tretinoin, or all-trans-retinol), fish oils (administered
as docosahexaenoic acid (DHA), omega-3 fatty acids or
eicosapentaenoic acid, fish-liver oils and cod-liver oil) or both, for
any duration, as a treatment for RP.
We included trials when the following interventions and
comparisons were used in studies.
1. For which participants received the following interventions:
• only fish oils or only vitamin A;
• fish oils along with any (one or more than one) type of other
vitamin(s);
• vitamin A along with any (one or more than one) type of
vitamin(s).
We included trials in which participants receiving the above-
mentioned interventions were compared to participants receiving
placebo, vitamins (other than vitamin A), or no therapy.
2. For which participants received the following interventions:
• both fish oils and vitamin A;
• both vitamin A and fish oils in combination with other vitamins.
We included trials in which participants receiving the above-
mentioned interventions were compared to participants receiving
placebo, vitamins (including vitamin A), or no therapy.
Types of outcome measures
Primary outcomes
Mean change in visual field sensitivity (measured in decibels (dB))
at one-year follow-up. We also prespecified that we would analyze
this outcome at other follow-up times using available data (i.e. two,
three, four, and five years). We planned that if the investigators
could not provide mean change values, we would report the
proportion of participants with visual field loss for these trials.
Visual field can be measured using diCerent instruments, such
as the Humphrey Field Analyzer and Goldmann perimeter. We
described the methods used to measure visual field (by instrument,
manual versus automated, threshold versus kinetic perimetry) and
programs used to analyze automated threshold perimetry (e.g.
30-2, 30/60-1) in the Characteristics of included studies table.
Secondary outcomes
• Visual acuity: in the protocol for this systematic review, we
specified the change in logMAR visual acuity at five-year follow-
up. We examined data at other follow-up times (one, two, three,
and four years' follow-up) as well, as these were reported in the
included trials.
• Electroretinography (ERG): we analyzed the log mean change
in ERG amplitude (rod response, mixed response, and cone
response) at one year. We also examined this outcome at
other follow-up times (two, three, four, and five years). When
ERG findings were reported in other ways, we summarized the
available data.
• Optical coherence tomography (OCT): analysis of this variable
included the change from baseline in tomographic features,
especially the junction between the photoreceptor outer
segments and inner segments, at one year and at other times of
follow-up as available.
Adverse e>ects (severe, minor)
We summarized any adverse outcomes reported in the included
trials. Specific adverse events of interest were systemic
complications such as liver injury, elevated blood lipid levels,
increased intracranial pressure, bone changes, teratogenicity
(association with birth defects), and ocular complications such as
loss of six or more lines of visual acuity at one-year follow-up.
Quality of life measures
We planned to report any quality of life measures associated with
patient satisfaction, subjective visual improvement, and any other
vision-related quality of life measures assessed by questionnaires
or other methods that were reported in the trials.
Follow-up
We included trials with follow-up of one year or longer in the review.
Where possible, we planned to conduct meta-analysis for trials with
similar lengths of follow-up.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist searched
the following electronic databases for RCTs and controlled clinical
trials. There were no language or publication year restrictions. We
last searched the electronic databases on 7 February 2020.
• Cochrane Central Register of Controlled Trials (CENTRAL; 2020,
Issue 2) (which contains the Cochrane Eyes and Vision Trials
Register) in the Cochrane Library (searched 7 February 2020)
(Appendix 1).
• MEDLINE Ovid (1946 to 7 February 2020) (Appendix 2).
• Embase.com (1947 to 7 February 2020) (Appendix 3).
• PubMed (1948 to 7 February 2020) (Appendix 4).
• Latin American and Caribbean Health Sciences Literature
database (LILACS) (1982 to 7 February 2020) (Appendix 5).
• metaRegister of Controlled Trials (mRCT) (www.isrctn.com/; last
searched 20 August 2013) (Appendix 6).
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• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov/; searched 7 February
2020) (Appendix 7).
• World Health Organization (WHO) International Clinical Trials
Registry Platform (ICTRP) (www.who.int/ictrp/en/; searched 7
February 2020) (Appendix 8).
• OpenGrey (www.opengrey.eu/; searched 7 February 2020)
(Appendix 9).
Searching other resources
We handsearched the reference lists of the publications from
studies eligible for inclusion in the review for information about
other possible trials. We used the Web of Science database to
identify additional studies that cited the included trials. We also
searched abstracts from the annual meetings of the Association for
Research in Vision and Ophthalmology (ARVO) and the American
Academy of Ophthalmology (AAO) electronically.
We did not contact individuals or organizations to identify trials for
this review.
Data collection and analysis
Selection of studies
Two review authors, working independently, assessed the titles
and abstracts identified by the searches. Each review author
classified the citations as 'definitely include,' 'possibly include
(unsure),' and 'definitely exclude.' We obtained the full-text
publications of listings classified as definitely include and possibly
include (unsure) to determine whether they were from studies that
met the inclusion criteria, and then reclassified them as 'include,'
'exclude,' or 'awaiting classification.' We scanned the reference lists
of the included studies manually to identify additional relevant
citations. For studies categorized as 'awaiting classification' by
both review authors, we requested additional information from the
study investigators for clarification.
Review authors were not masked to any trial details in this process.
Disagreements were resolved through discussion. We tabulated
excluded trials along with reasons for exclusion.
Data extraction and management
Two review authors, working independently, extracted data from
the publications of all included studies using data extraction
forms developed by Cochrane Eyes and Vision and pilot-tested
specifically for this review. Any discrepancies were resolved
through discussion.
We extracted the following information from each study.
• Methods: method of randomization, allocation concealment,
masking (blinding), number randomized to each trial arm,
exclusions aSer randomization, losses to follow-up, and unusual
study design features.
• Participants:  country where participants were enrolled, age,
sex, and inclusion/exclusion criteria.
• Interventions: details of test intervention and comparison
intervention (control) including dose and frequency of
administration and duration of intervention.
• Outcomes:  visual field (primary outcome), visual acuity
(secondary outcome), ERG measurements (secondary
outcome), adverse events, any other outcomes assessed, and
percentage of participants for whom no outcome data were
reported.
• Follow-up and analysis: length of follow-up, reasons stated for
dropouts or withdrawal, compliance, and methods for analysis.
• Others: additional details (such as funding sources) and
publication year.
When any of the above data were missing from publications of a
trial, we attempted to contact the study investigators for further
information. If we did not receive a response within two months
(aSer three emailed messages and one telephone contact), we
proceeded without the missing information.
One author (SAA) entered data into the Review Manager 5
soSware (Review Manager 2014), and the second review author
(SGS) verified the data entered against data extracted from the
publications.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias of the
included studies according to the following criteria as described
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2017). We graded each of the six 'Risk of bias'
domains as low, high, or unclear (indicating either uncertainty or a
lack of information). We provided a description for each judgement
of bias.
• Adequate sequence generation (selection bias): we
categorized a study as being at low risk if the sequence was
generated using a computer program or a random-numbers
table. We categorized all other methods as high risk or unclear
risk.
• Allocation concealment (selection bias): we categorized a
study as being at low risk if the participants or the investigators
enrolling the participants could not determine the assignments
(e.g. use of central allocation, sequentially numbered, opaque,
sealed envelopes). We categorized all other methods as being at
high risk or unclear risk.
• Masking of participants: we assessed whether the methods
used to mask participants were adequate. When adequate
methods to mask knowledge of the assigned intervention were
used and described, such as similar-looking pills administered
at similar times of the day, we categorized the study as being at
low risk of bias. We categorized all other methods as being at
high risk or unclear risk.
• Masking of care providers: we assessed whether the methods
used to mask physicians and other care providers were
adequate. When adequate methods to mask knowledge of
the assigned intervention were used and described in specific
language indicating masking, we categorized a study as being
at low risk of bias. We categorized all other methods as being at
high risk or unclear risk.
• Masking of outcome assessors: we assessed whether the
methods used to mask outcome assessors with regard to the
treatment arm were adequate. When adequate methods to
mask knowledge of the assigned intervention were used and
described, such as analyzing each assessment (such as visual
field) without access to prior tests, we categorized a study as
being at low risk of bias. We categorized all other methods as
being at high risk or unclear risk.
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• Incomplete outcome data: we assessed included trials for
exclusions aSer randomization and losses to follow-up along
with the reasons for missing outcome data to determine the risk
of bias. We categorized a study as being at low risk of bias when
there were no missing outcome data, or the reasons for missing
outcome data were not related to the true outcome; the reasons
for missing data were similar across groups; or the missing data
had been imputed using appropriate methods. We categorized
all other reasons for missing outcome data as being at high risk
or unclear risk.
Measures of treatment e>ect
We planned to use risk ratios (RR) (i.e. RR and 95% confidence
intervals (CI)) as the measure of eCect for dichotomous outcomes
(proportion of participants with new visual field defects, visual
acuity data reported as dichotomous outcomes, and proportion of
participants with adverse events). We calculated a mean diCerence
(MD) for continuous outcomes (mean change in visual field, logMAR
visual acuity, and mean change in ERG amplitude).
We decided a priori that wherever visual acuity data were reported
as a dichotomous outcome, we would attempt to contact the
investigators for mean change values. If no additional data were
available, we would analyze visual acuity as a dichotomous
outcome (such as proportion of participants losing two or more
lines of visual acuity) using the data in the trial report.
We planned to summarize the electroretinogram either as a
continuous outcome or a dichotomous outcome based on the
available data. We analyzed the mean change in ERG amplitude as
a continuous outcome. We planned to analyze the proportion of
participants with non-detectable ERG patterns in response to high-
frequency flickers (30 or 31 Hz) as a dichotomous outcome.
Unit of analysis issues
Since participants in the included trials were given systemic
treatment, the unit of analysis was the individual. We planned that
when data were available for both eyes of an individual, we would
perform an analysis for the average of the two eyes for continuous
outcomes. For vision-related dichotomous outcomes (e.g. visual
acuity), we would use the eye as the unit of analysis.
Dealing with missing data
We contacted the study investigators for further information on
trials with publications that did not report outcomes on all
randomized participants. We planned that if they did not respond
aSer three emailed messages and telephone contacts, initiated
within two months, we would assess the study on the basis of
the available information. One author responded, but was unable
to provide any additional data or information that was missing
from the publication. We attempted to extract data on standard
deviations for the change from baseline if a P value or a CI was
reported, using the methods described in Section 16.1.3 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). We did not attempt to impute the standard deviations
using possible values of correlation coeCicients. We conducted
analyses by the intention-to-treat principle, with all participants
analyzed in the group to which they had been randomized, to the
extent permitted by the methods described here. If the data in the
publication or the trial investigators were unable to provide data to
permit an intention-to-treat analysis, we conducted analysis on the
available number of participants in the publication.
Assessment of heterogeneity
We assessed clinical and methodological heterogeneity by
examining the characteristics of the included studies and by visual
examination of the forest plots; we used the I2 statistic and Chi2 test
to assess statistical heterogeneity.
Assessment of reporting biases
Had there been a suCicient number of included trials, we would
have used a funnel plot to identify evidence of publication bias.
We did not have access to the trial protocols to assess selective
outcome reporting.
Data synthesis
We prespecified in the protocol for this review that if we found
substantial heterogeneity across studies, either because of clinical
heterogeneity (variability in types of participants, interventions,
follow-up, etc.) or statistical heterogeneity (I2 values greater than
50%, statistically significant Chi2 test for heterogeneity), we would
not attempt a meta-analysis but would present an estimate of
eCect and associated 95% CI for each individual trial. We would
conduct a fixed-eCect meta-analysis if there was little variation
between trials, if we had two or three trials and there was no clinical
heterogeneity and minimal statistical heterogeneity (as indicated
by I2 values); we would conduct a random-eCects meta-analysis
when there was no clinical heterogeneity but there was moderate
statistical heterogeneity (I2 values of 30% to 50%).
Subgroup analysis and investigation of heterogeneity
Had we found substantial heterogeneity, we would have explored
the reasons for this heterogeneity by examining details from
the trials including types of participants (baseline characteristics
including severity of the disease, genetic profile, and syndromic
or non-syndromic RP), interventions (frequency and dose),
duration of follow-up, methodological characteristics such as
losses to follow-up, reasons for losses to follow-up, and outcome
measurement methods. We provided a qualitative analysis and
summary of the variability across included trials. If the included
trials provided suCicient data, we would conduct a subgroup
analysis based on whether participants had syndromic or non-
syndromic RP.
Sensitivity analysis
We planned to conduct sensitivity analyses to assess the impact
of excluding studies with poor methodological quality (high risk
of bias for all or a large majority of 'Risk of bias' domains) and
industry-funded studies, however we did not perform this due to
the few number of included studies.
'Summary of findings'
We summarized the main findings for each comparison of interest,
including strengths and limitations of evidence, for primary,
secondary, and adverse outcomes, using the GRADE approach
(GRADEpro 2014). We assessed the quality of evidence for each
outcome as 'high,' 'moderate,' 'low,' or 'very low' according to
the following criteria as described in Chapter 12 of the Cochrane
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Handbook for Systematic Reviews of Interventions (Schünemann
2011a; Schünemann 2011b).
• High risk of bias among included studies.
• Indirectness of evidence.
• Unexplained heterogeneity or inconsistency of results.
• Imprecision of results (i.e. wide confidence intervals).
• High probability of publication bias.
We presented a 'Summary of findings' table for each comparison of
interest where data were available. The comparisons include either
only fish oils or only vitamin A, or both; fish oils along with any (one
or more than one) type of other vitamin(s); vitamin A along with any
(one or more than one) type of vitamin(s); or both vitamin A and fish
oils in combination with other vitamins compared with placebo,
vitamins (other than vitamin A), or no therapy. We included the
following outcomes at one year or other follow-up times in the
Summary of findings 1.
• Mean change in visual field sensitivity
• Visual acuity
• Electroretinography (ERG)
• Optical coherence tomography (OCT)
• Adverse events.
R E S U L T S
Description of studies
Results of the search
The search in the previous version of the review conducted in
August 2013, excluded seven studies with reasons and included
three trials (Rayapudi 2013). Through an updated electronic search
on 20 November 2018, we retrieved a total of 2028 titles and
abstracts. ASer removing duplicate records, we reviewed 1287 titles
and abstracts for eligibility, excluding 1267 of these records. We
screened 20 full-text reports, excluded 14 with reasons, classified
one as ongoing study and one new RCT (HoCman 2014) added
in this update. In a top-up search conducted on 7 February 2020,
we identified 1821 records, screening 239 records aSer removal of
duplicates. We retrieved two full-text reports and further excluded
one report with reasons, classifying one record as an ongoing trial
(Figure 1). Overall, we included four RCTs, excluded 22 studies
(22 records), assessed two studies (two records) as ongoing trials.
We did not identify any additional studies through searching the
reference lists of the included studies or the Web of Science
database.
 
Figure 1.   Results from searching for studies for inclusion in the review.
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Included studies
Detailed characteristics of each included trial are presented in
the Characteristics of included studies table and Table 1. Table
1 summarizes the study design, baseline characteristics of the
participants, and interventions across the included trials.
Study design and setting
Two trials recruited participants from the USA (Berson 2004a;
HoCman 2004), and the other two (Berson 1993, HoCman 2014)
recruited participants from the USA and Canada. Three studies
were RCTs with a parallel-group design, and one employed
a factorial design (Berson 1993). Participants were primarily
recruited from eye registries and clinical centers supported by
the Foundation Fighting Blindness (FFB). HoCman 2004 recruited
participants from the Southwest Eye Registry and from the clinical
centers supported by FFB, and HoCman 2014 recruited from the
Southwest Eye Registry, the FFB database, and referrals from US
and Canadian ophthalmologists. Berson 1993 and Berson 2004a
recruited participants from the Baltimore Eye Registry, the centers
supported by FFB, and the contacts of private ophthalmologists.
Types of participants
A total of 944 participants were enrolled, and 881 were analyzed.
The trials varied in size from 44 participants (HoCman 2004) to 601
participants (Berson 1993). The age of participants in the included
trials ranged from 4 to 55 years. HoCman 2004 and HoCman 2014
included children and participants of a younger age range (4 to
38 years and 7 to 31 years, respectively) than the other two trials.
Two trials included both male and female participants (Berson
1993; Berson 2004a), while the other two trials enrolled only male
participants (HoCman 2004; HoCman 2014). In all four trials, RP
was diagnosed in all participants by an ophthalmologist. None of
trials reported RP according to specific subtypes or subdiagnosis
and treatment response.
People with atypical forms of retinitis pigmentosa (such as
unilateral RP, sector RP, paravenous RP) and most syndromic
forms of RP (Bardet-Biedl syndrome, Bassen-Kornzweig syndrome,
Refsum disease, Usher's syndrome type 1) were not included in any
of the four trials. However, two trials included people with some
syndromic forms of RP (including Usher's syndrome type 2 (RP
associated with partial hearing loss)) (Berson 1993; Berson 2004a).
Participants with all levels of genetic predisposition were included
in these two trials (autosomal dominant, autosomal recessive, X-
linked, dominant with mutation, isolate and undetermined), while
the other two trials included only participants with X-linked RP
(HoCman 2004; HoCman 2014).
DiCerent instruments were used to measure visual field in the
included trials, resulting in diCerent measures of baseline values.
Kinetic perimetry was used in Berson 1993, whereas static
perimetry was used in the remaining three trials. Guidelines for
converting results between kinetic and static perimeters have been
reported by Anderson and colleagues (Anderson 1989). Participants
enrolled in Berson 2004a had a baseline Humphrey Field Analyzer
(HFA) 30-2 program total point score ≥ 250 dB, using size V test
light, whereas those enrolled in Berson 1993 had a central visual
field diameter of ≥ 8 degrees (Goldman V-4-e). In HoCman 2014,
participants had an HFA 30-2 program with spot size V, except
participants with fields > 30 degrees, who used program 30/60-2. A
baseline visual field result was not specified in HoCman 2004.
Visual acuity was measured using Early Treatment Diabetic
Retinopathy Study (ETDRS) charts in all four trials. Participants
enrolled in Berson 1993 and Berson 2004a were required to have
a baseline minimum visual acuity of 20/100 (Snellen equivalent),
but a baseline visual acuity minimum was not specified in the
remaining trials.
Two trials included participants with greater than 0.68 µV of
cone ERG (Berson 2004a; HoCman 2004), and one trial included
participants with greater than 0.64 µV of cone ERG (HoCman
2014). The remaining trial included participants with cone ERG
of at least 12 µV (Berson 1993). The percentages of participants
with a measurable rod response at baseline were 61% (366/601),
55% (114/208), and 50% (22/44) in Berson 1993, Berson 2004a,
and HoCman 2004, respectively. In all studies but HoCman 2014,
response amplitude to cone ERG of less than 2 µV was narrowband
amplified in order to reliably distinguish responses greater than
0.05 µV from noise.
We identified clinical heterogeneity among participants in the
included trials regarding several aspects including age of the
participants, genetic predisposition, gender, and baseline severity.
Participants in HoCman 2004 and HoCman 2014 were younger than
those in Berson 1993 and Berson 2004a; the mean ages were: 16 ±
9 years (HoCman 2004); 14.9 ± 1.1 (placebo) and 16.1 ± 1.4 (DHA)
years (HoCman 2014); 32.5 ± 0.7 years (Berson 1993); and 37.8 ± 0.90
years (Berson 2004a). The baseline severity of RP varied among the
trials as described above for baseline values of ERG, visual field,
and visual acuity. We were unable to extract data for the outcomes
specified in the protocol for this review based on the genetic profile
of participants.
Types of interventions
The trials included in this review evaluated diCerent interventions.
Docosahexanoic acid (DHA) only was administered in two trials
(HoCman 2004; HoCman 2014). Vitamin A (along with vitamin E for
some participants) was administered in Berson 1993. Both DHA and
vitamin A were administered in Berson 2004a. Doses also varied
between trials. HoCman 2004 administered 400 mg of DHA per day,
whereas Berson 2004a administered 1200 mg of DHA per day. In
HoCman 2014, 30 mg/kg/d of DHA was administered, ranging from
600 mg to 3600 mg of DHA per day. Vitamin A was administered at
a dose of 15,000 international units (IU) in both trials in which it
was used (Berson 1993; Berson 2004a). Interventions (vitamin A and
DHA) were administered orally in the form of gelatin capsules for
a minimum period of four years. However, in Berson 1993, 43% of
participants received the test or control intervention for six years.
Comparison intervention: DHA was compared to placebo in
HoCman 2004 and HoCman 2014; DHA + vitamin A was compared
to vitamin A alone in Berson 2004a; and vitamin A was compared to
trace vitamins group (vitamin A trace + vitamin E trace) in Berson
1993.
Excellent compliance was documented in Berson 1993 (94% of
capsules were consumed in any given year by 88% of participants)
and Berson 2004a (92% of DHA capsules and 94% of vitamin A
capsules were consumed over all four years). In HoCman 2014,
mean adherence to protocol was 89.4% in the DHA group and 84.6%
in the placebo group by capsule count monitoring. HoCman 2004
reported poor compliance in 5 of 44 participants (11.4%), using
analysis of red blood cell levels of DHA.
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Types of outcomes
Our primary outcome measure, visual field sensitivity, was
analyzed as primary outcome in Berson 2004a, and as a secondary
outcome measure in the three other trials (Berson 1993; HoCman
2004; HoCman 2014), in which annual change in full field cone ERG
amplitude was the primary outcome measure. How each of the
visual outcomes in the included trials was analyzed is shown in
Table 2.
Excluded studies
We excluded a total of 22 records; reasons for their exclusion are
shown in the Characteristics of excluded studies table.
Ongoing studies and studies awaiting classification
We identified two ongoing studies (see Characteristics of ongoing
studies). No trial was classified as awaiting classification.
Risk of bias in included studies
We evaluated the risk of bias for all of the included trials using
the six prespecified domains described in the Assessment of risk
of bias in included studies section. We categorized blinding of
outcome assessors and incomplete outcome data reporting into
three criteria for primary and secondary outcomes, and so recorded
a total of 12 criteria in the Characteristics of included studies and
Figure 2. We found Berson 1993, HoCman 2004, and Berson 2004a to
have a low overall risk of bias. Summary of 'Risk of bias' assessment
is shown in Figure 2.
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Berson 1993 + + + + + + + + + + ? +
Berson 2004a + + + + + + + + + + ? +
Hoffman 2004 ? + + + + + + + + + ? +
Hoffman 2014 + ? + + + + + - - - - +
 
Allocation
In three trials the random sequence was generated adequately by
using computer-generated random numbers (Berson 1993; Berson
2004a; HoCman 2014). HoCman 2004 used a cluster-RCT strategy,
as relatives were randomized together to the same intervention
to eliminate a potential for mixing of capsules. In the Methods,
we stated that we intended to exclude cluster-randomized trials,
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and although HoCman 2004 mentioned that the relatives were
randomized to same intervention using a cluster-RCT strategy, the
strategy was not clearly and adequately described, and it was
not clear how many relatives were randomized or what percent
of randomized individuals were randomized using a cluster-
RCT strategy. In addition, upon our assessment, we found that
individuals were randomized to treatment groups. We therefore did
not consider HoCman 2004 to be a cluster-randomized trial, and so
decided to include it.
Allocation was implemented using a centralized system in Berson
1993 and Berson 2004a, which implies that personnel enrolling
participants could not determine the next assignment. It was
unclear whether there was adequate allocation concealment in the
remaining two trials.
Blinding
All four included trials masked all personnel (participants,
investigator, caregiver, outcome assessors) adequately. The
outcome assessors were masked to both primary (visual field) and
secondary (visual acuity and ERG) outcomes.
Incomplete outcome data
In HoCman 2004, 44/44 participants completed three years
of follow-up, and 41/44 participants completed four years of
follow-up. Three people missed visits over the entire span
of study. The trialists imputed data for missed visits using
the 'last observation carried forward' method and performed
intention-to-treat analysis. In Berson 2004a and Berson 1993, the
trialists imputed missed measurements using multiple imputation
methods. All trials accounted for incomplete outcome data
adequately. In HoCman 2014, 12/41 (29.3%) participants in the DHA
group and 15/37 (40.5%) participants in the placebo group who
were randomized were not included in the final analysis at four
years of follow-up. We assessed this study as at high risk of bias for
incomplete outcome data.
Selective reporting
In one study (HoCman 2014), the outcome loss of peripheral visual
fields, which was listed in the ClinicalTrials.gov registration, was not
described in the publication, therefore we assessed this study as at
high risk of bias for selective outcome reporting. We did not have
access to protocols or to other information that would have allowed
us to assess selective reporting in the remaining three trials.
Other potential sources of bias
We did not assess the potential for publication bias using a funnel
plot or other means, given that we identified only four trials that
were eligible for inclusion.
E>ects of interventions
See: Summary of findings 1 Vitamin A and fish oils
(docosahexaenoic acid) compared to placebo, vitamins (including
vitamin A), or no therapy for retinitis pigmentosa
All of the included trials reported visual field, visual acuity, and
ERG as either a primary outcome or secondary outcome. One trial
performed OCT (HoCman 2014).
We elected not to conduct a meta-analysis because of clinical
heterogeneity in the types of participants included and diCerences
in the intervention and comparison groups studied (as described
in earlier sections of this review) across the included trials. In
addition, we were unable to extract data from the included trials
on outcomes prespecified in the protocol for this review. Although
the outcomes measured in all four trials included visual field, ERG
amplitude, and visual acuity, they were analyzed and reported in
ways that did not allow quantitative synthesis and comparison
of data. We were thus unable to report a summary eCect of
interventions in terms of the outcomes prespecified in the protocol.
We have presented a narrative summary of evidence reported in
included studies below.
Table 2 and Table 3 illustrate the variability across the included
trials in defining the outcome variable and its analysis for visual
field, visual acuity, and ERG amplitude.
Visual field (4 studies involving 881 participants)
Three trials examined the treatment eCect associated with DHA
(Berson 2004a; HoCman 2004; HoCman 2014), and one trial
examined the eCect of vitamin A on visual field (Berson 1993),
although they reported diCerent measurement parameters. All
studies measured visual field either as a primary outcome,
Berson 2004a, or secondary outcome (Berson 1993; HoCman 2004;
HoCman 2014). One trial reported that the annual rate of visual
field loss over four years was significantly smaller in the DHA group
compared to the placebo group (HoCman 2014), while the other
three trials found no evidence of diCerence in rates of loss of visual
field over four years between the treatment and control groups.
The primary outcome measure reported in Berson 2004a (208
participants) was the measurement of static perimetric sensitivities
(total point score, i.e. overall assessment) on the HFA 30-2 program
with size V target. There was no evidence of diCerence in the
mean annual rates of decline of visual field sensitivity between
the intervention group (participants receiving DHA and vitamin
A, 36.95 ± 3.36 dB per year) and the control group (participants
receiving placebo and vitamin A, 37.68 ± 3.36 dB per year, P =
0.88). The investigators reported the combined total point score
on the HFA 30-2 and 30/60-1 programs as a secondary outcome
measure. Again, there were no evidence of a diCerence in the mean
annual rates of decline between the intervention group (57.21 ±
4.90 dB per year) and the control group (59.59 ± 4.90 dB per year,
P = 0.73). However, in a separate publication (Berson 2004b), the
investigators reported a post hoc subgroup analysis (participants
taking vitamin A prior to entry into the trial compared to those
not taking vitamin A prior to entry into the trial). They concluded
that among participants not taking vitamin A prior to entry into
the trial, the mean annual rates of decline of central and total field
sensitivity may be lower in the intervention group (30 participants;
DHA + vitamin A) than in the control group (35 participants; placebo
+ vitamin A) in the first and second years of follow-up, but not in the
third and fourth years of follow-up (data not shown).
HoCman 2014 (60 participants) assessed visual field sensitivity by
using HFA 30-2 program with spot size V, and program 30/60-2
for those who had field more than 30 degrees. The investigators
reported that although there was no diCerence in mean values
between the DHA and placebo groups, the annual rate of change
over four years probably favors the DHA versus placebo group in
foveal (−0.02 ± 0.05 (standard error (SE)) dB versus −0.47 ± 0.03 dB, P
= 0.039), macular (−0.42 ± 0.05 dB versus −0.85 ± 0.03 dB, P = 0.031),
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peripheral (−0.39 ± 0.02 versus −0.86 ± 0.02 dB, P < 0.001), and total
visual field sensitivity (−0.39 ± 0.02 versus −0.86 ± 0.02 dB, P < 0.001).
In contrast, HoCman 2004 reported the focal assessment of change,
presented in mean field defect (average of all diCerences from
mean normal) using the HFA 30-2 program with size III target
and the 30/60-2 program for participants with suCicient peripheral
function. There was no evidence of a diCerence between the
intervention (DHA, 2.4 ± 3.66 dB over four years) and control group
(placebo, 1.4 ± 1.32 dB over four years); P = 0.29.
In Berson 1993 (572 participants), the percentage decline in the
residual visual field (on kinetic Goldmann perimetry) was 5.6% in
the intervention group (vitamin A + vitamin E trace) and 5.9% in the
control group (vitamin A trace + vitamin E trace), with no diCerence
between the two groups. We graded the certainty of evidence for
this outcome in all four studies as very low, downgrading for risk of
bias, inconsistency, and imprecision.
Visual acuity (4 studies involving 881 participants)
Visual acuity was assessed as a secondary outcome using the
ETDRS charts in all trials included in this review. Three trials
examined the eCect of DHA on visual acuity (Berson 2004a; HoCman
2004; HoCman 2014), and one trial examined the eCect of vitamin
A on visual acuity (Berson 1993). All of the included studies showed
no diCerence in rates of loss of visual acuity over four years between
the intervention and comparison groups.
Berson 2004a (208 participants) reported the ETDRS visual acuity
as number of letters per year. Both the (DHA and vitamin A) and
(placebo and vitamin A) groups lost 0.7 letters of ETDRS visual
acuity per year.
In HoCman 2004 (41 participants), the mean change from baseline
visual acuity aSer four years' follow-up was 0.05 logMAR units
(95% confidence interval (CI) −0.04 to 0.14) (i.e. 2.5 letters) among
participants treated with DHA, and 0.06 logMAR units (95% CI
−0.02 to 0.14) among participants treated with placebo, with no
evidence of a diCerence between the two groups (mean diCerence
−0.01 logMAR units, 95% CI −0.14 to 0.12) (i.e. less than one letter
diCerence).
In HoCman 2014 (60 participants), annual change in mean number
of letters correct was −0.8 in the DHA group and 1.4 letters in the
placebo group, with no evidence of a between-group diCerence
observed (P = 0.19).
In Berson 1993 (572 participants), decline in ETDRS visual acuity
was 1.1 letters per year in the intervention group (vitamin A +
vitamin E trace) and 0.9 letters per year in the control group (vitamin
A trace + vitamin E trace), with no evidence of a diCerence between
the groups.
We assessed the certainty of the evidence across all four studies
as very low, downgrading for risk of bias, inconsistency, and
imprecision.
Electroretinography (4 studies involving 881 participants)
Three trials examined the treatment eCect associated with DHA
on ERG amplitudes (Berson 2004a; HoCman 2004; HoCman 2014),
and one trial examined the eCect of vitamin A (Berson 1993). Both
rod and cone ERG amplitudes were measured in all four trials. The
results varied across the four trials.
In Berson 2004a (208 participants), the eCect of vitamin A and
DHA on cone ERG amplitude was reported in terms of mean rate
of decline of remaining 30 Hz ERG amplitude per year of follow-
up. Over four years, analysis of 30 Hz cone ERGs showed that the
mean annual rates of decline of remaining function were 9.92% in
the group receiving DHA and vitamin A, and 10.49% in the group
receiving only vitamin A, with no diCerence between the two groups
(P = 0.64).
In HoCman 2004 (41 participants), the average diCerence in change
from baseline in cone ERG amplitude between DHA and placebo
aSer four years' follow-up was 0.07 log μV (95% CI −0.04 to 0.17).
In calculating the sample size for HoCman 2004, the trial was
powered to detect an anticipated change of 0.085 log units per
year in cone ERG amplitude. The observed decline in cone ERG
amplitude in the control group was only 0.066 log units per year.
This trial may thus have not been adequately powered to detect the
prespecified treatment eCect. In a subgroup analysis of HoCman
2004, investigators reported that there may be an eCect of DHA
on rod ERG amplitude (P = 0.04), but not on cone ERG amplitude
in children under 12 years of age (P = 0.86). Conversely, the
investigators found that there may also be an eCect of DHA on cone
ERG amplitude (P = 0.04) but not on rod ERG amplitude among
children 12 years or older.
In HoCman 2014 (60 participants), 31 Hz cone ERG amplitude, rod
and maximal ERG amplitude, and cone ERG implicit time were
assessed annually up to four years. There was no evidence of a
diCerence with respect to yearly rates of change between the DHA
and placebo group in 31 Hz cone ERG amplitude (mean ± SE) (−0.028
± 0.001 log μV versus −0.022 ± 0.002 log μV; P = 0.30), rod ERG
amplitude (mean ± SE) (−0.010 ± 0.001 log μV versus −0.023 ± 0.001
log μV; P = 0.27), maximal ERG amplitude (mean ± SE) (−0.042 ±
0.001 log μV versus −0.036 ± 0.001 log μV; P = 0.65), and cone ERG
implicit time (mean ± SE) (no change over four years (data not
reported) versus 0.12 ± 0.02; P = 0.77) over four years of follow-up.
We judged the certainty of the evidence for this outcome across all
four studies as very low, downgrading for risk of bias, inconsistency,
and imprecision.
Berson 1993 (572 participants) reported an eCect of vitamin A
on the mean change in log ERG amplitude from baseline (P =
0.01). A previous cohort study had estimated a decline of 17%
of remaining cone ERG amplitude per year among patients with
RP (Berson 1985), and the Berson 1993 trial was designed using
this assumption for sample size calculation. The 1985 trial report
described that participants with measurable cone ERG amplitude
(≥ 0.68 μV) at baseline showed a decline of 10% per year (in the
trace group), whereas participants in the trace group with < 0.68
μV cone ERG amplitude did not show any measurable rate of
decline in cone ERG amplitude. The Berson 1993 authors inferred
from these observations that the eCects of the intervention might
be detected only in participants who had minimum cone ERG
amplitude of 0.68 μV at baseline. Accordingly, Berson 1993 reported
a post hoc subgroup analysis that included only participants who
had high cone ERG amplitude at baseline. The findings from
this subgroup analysis indicated that daily supplementation with
15,000 IU vitamin A may reduce the annual rate of loss of remaining
cone ERG amplitude compared to people not receiving this dose of
vitamin A (8.3% decline per year in the vitamin A group versus 10%
decline per year in the non-vitamin A group; P < 0.001), although the
clinical relevance of this diCerence is questionable (Berson 1993).
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A probable eCect was also observed for this outcome when the
analysis included all randomized participants in this trial (6.1%
decline per year in the vitamin A group versus 7.1% decline per year
in the non-vitamin A group; P = 0.01). These findings from subgroup
analyses have not been replicated or substantiated by findings in
any of the remaining trials. We rated the certainty of the evidence
for this outcome across all four trials as very low, downgrading for
risk of bias, inconsistency, and imprecision.
Optical coherence tomography (1 study involving 51
participants)
Optical coherence tomography data were available over two years
in HoCman 2014 (51 participants). No evidence of a diCerence was
seen in ellipsoid zone constriction (P = 0.87) over two years. We
assessed the certainty of the evidence as very low, downgrading for
risk of bias, inconsistency, and imprecision.
Adverse e>ects (4 studies involving 944 participants)
HoCman 2014 (60 participants) reported that 27 participants
(34.6%) experienced 42 treatment-related or possibly related
treatment-emergent adverse events (22 in the DHA group, 20 in
the placebo group) during four years of treatment. No severe
treatment-emergent adverse events were observed in this study.
No toxicity or adverse events were reported in the other three trials.
We rated the certainty of the evidence across all four studies as very
low, downgrading for risk of bias, inconsistency, and imprecision.
D I S C U S S I O N
Summary of main results
We did not find clear evidence for the benefit of treatment with
vitamin A or DHA, or both, for people with RP for the outcomes
prespecified in our protocol, with the exception of one subgroup
in Berson 1993, in which participants with high cone amplitude
at baseline appeared to have had a reduced rate of loss of
remaining cone function compared to non-supplemented controls.
The findings from this subgroup analysis have not been replicated
in other RCTs. Where data were available for the mean change in
visual field, visual acuity, and cone ERG amplitude aSer four years
of follow-up in adult participants with X-linked RP (HoCman 2004),
there was no statistically significant benefit. Berson 1993 described
a statistically significant protective eCect of vitamin A on the annual
mean change in cone ERG amplitude.
Despite testing visual fields with two diCerent visual field
instruments, diCerent automated strategies and outcome
measures, there was no demonstrable eCect of therapy on visual
field outcome. Berson 1993 initially performed kinetic Goldmann
visual fields with V-4-e white test light on a 601 participants aged
18 to 49 years. Comparing treatment groups and controls, there
was no treatment eCect on visual field area; however, the authors
noted a positive trend correlating visual field area and change in 30
Hz ERG amplitude, suggesting that participants receiving vitamin A
had a slower rate of decline in visual field area over the four years
of treatment.
In a follow-up study in 2004 (Berson 2004a), the investigators
studied central and peripheral visual field changes using the
Humphrey Field Analyzer (HFA). They assessed central field with
the HFA 30-2 program and total field with the combined HFA 30-2
and 30/60-1 programs over three to four years. A size V target was
used centrally and peripherally using the FASTPAC test. There was
significant visual field loss over all the points measured in the
treatment and the control groups: centrally (37 to 38 dB per year
to the HFA 30-2 program condition) combined with overall visual
field loss (57 to 60 dB to the HFA 30-2/30/60-1 programs combined).
The trialists reported: “these total point score declines summarize
about 0.5 dB and 0.4 dB per year, respectively, for an average
location in the visual field.”
HoCman 2004 studied visual fields in 21 participants in the
treatment group and 23 controls using the HFA. A 30-2 static
program with spot size III was used to assess 74 locations within
the central 30 degrees. Participants who had retained peripheral
function were also tested at 72 locations with the 30/60-2 program.
As the trialists reported, “The visual field parameter selected for
evaluation was the mean field defect (average of all diCerences
from mean normal; dB),” and the mean defect changed by 1.4 ± 1.32
dB in the placebo (control) group compared with 2.4 ± 3.66 dB in the
treatment group. The authors expressed concern about the young
age of participants doing visual field testing at the beginning of the
study.
HoCman 2014, the most recent study, included 78 participants aged
7 to 31 years (41 in the DHA group and 37 in the placebo group).
Visual field sensitivity was assessed by using HFA program 30-2 with
spot size V, and program 30/60-2 for those who had field more than
30 degrees. Trialists reported that although mean values were not
significantly diCerent between the DHA and placebo groups, annual
rate of change over four years showed a statistically significant
diCerence in favor of the DHA group in foveal (DHA −0.02 ± 0.55
(SE) dB, placebo −0.47 ± 0.03 dB, P = 0.039), macular (DHA −0.42 ±
0.05 dB, placebo −0.85 ± 0.03 dB, P = 0.031), peripheral (DHA −0.39
± 0.02, placebo −0.86 ± 0.02 dB, P < 0.001), and total visual field
sensitivity (DHA −0.39 ± 0.02, placebo −0.86 ± 0.02 dB, P < 0.001).
The authors also reported that 27 participants (34.6%) experienced
42 (22 in DHA group, 20 in placebo group) treatment-related or
possibly related treatment-emergent adverse events during four
years of treatment.
Overall completeness and applicability of evidence
Small, non-randomized pilot studies (e.g. Tcherkes 1950 and
Dagnelie 2000) have reported evidence of eCectiveness of vitamins
in the treatment of RP, but the four well-designed, well-executed
RCTs included in this review did not, either individually or
collectively. However, one of the four studies found that annual
rate of change over four years showed a statistically significant
diCerence in favor of the DHA group in foveal and total visual
field sensitivity. The available data do not indicate a significant
beneficial eCect of DHA or vitamin A on progression of loss of visual
acuity and visual field. Furthermore, there was no evidence that the
eCects of vitamin A or combination of vitamin A and DHA diCered
according to the genetic profile of the participants, as assessed in
Berson 1993 and Berson 2004a.
The trials included in this review enrolled participants with
common forms of RP. None of the trials included participants
with atypical forms of RP (e.g. paravenous retinitis pigmentosa,
clumped pigmentary retinal degeneration, sector retinitis
pigmentosa, or unilateral retinitis pigmentosa); most syndromic
forms of RP (Refsum disease, Bardet-Biedl syndrome, Usher's
syndrome type 1 (i.e. retinitis pigmentosa with profound congenital
deafness)); or RP associated with hereditary abetalipoproteinemia
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(i.e. Bassen-Kornzweig syndrome). In addition, none of the
included trials involved pregnant women, people with weight and
height under the 5th percentile for a given age and sex, those with
liver malfunction, those over 55 years of age, and people with a
more advanced stage of the disease (visual acuity < 20/100, central
visual field diameter < 8 degrees, or people with 30 Hz cone ERG
amplitude of < 0.5 μV in response to 0.5 Hz white light or < 0.12 μV
in response to 30 Hz white flickering light).
Quality of the evidence
We determined that three included trials had a low risk of bias for
the domains assessed (Berson 1993; Berson 2004a; HoCman 2004).
We assessed HoCman 2014 as at high risk of bias for incomplete
outcome data and selective outcome reporting due to substantial
losses to follow-up and because one outcome, loss of peripheral
visual fields, was listed in the ClinicalTrials.gov registration but not
reported in the publication.
The results described in the trials are valid. However, we were
unable to extract suCicient data on the outcomes specified in our
protocol from the results described in the trial reports. The included
trials appear to have been well designed and conducted. However,
the conclusions drawn from the data that supplemental vitamin A
or vitamin A along with DHA slows the progression of RP were based
on the findings through ERG measurements rather than visual field
or visual acuity.
Potential biases in the review process
The descriptions of potential biases in the review process pertain to
the current status of availability of data. We will revise our findings
based on response from trial authors regarding data on outcomes.
We were unable to extract data from the text, tables, or figures for
the outcomes specified in the protocol for this review. In one case,
the mean cone ERG amplitude was available for both treatment
groups from a figure, but we could not extract the standard error for
the diCerence in mean change from baseline between the groups.
Communicating with authors should not introduce selection bias
into the review (Borly 2001), and may result in the availability
of more data for assessment, since we are working with a small
number of included trials and are unlikely to be able to conduct a
meta-analysis.
Because only four trials met inclusion criteria for this review,
heterogeneity of the compared interventions was allowed.
Specifically, the comparisons were as follows: vitamin A, vitamin
E, vitamin A plus vitamin E, and trace amounts of both vitamins
(Berson 1993); vitamin A plus DHA versus vitamin A plus control
capsules (Berson 2004a); DHA versus placebo capsules (HoCman
2004); and DHA plus a multivitamin versus a placebo plus a
multivitamin (HoCman 2014). Consequently, two trials compared
DHA with placebo (HoCman 2004; HoCman 2014); one trial
compared vitamin A plus DHA with vitamin A alone (Berson 2004a);
and one trial compared vitamin A with vitamin E (Berson 1993). We
judged this heterogeneity to be an acceptable trade-oC to permit
the inclusion of as many relevant trials as possible. In addition,
results were not combined in the analyses.
Agreements and disagreements with other studies or
reviews
This review is generally in agreement with other published reviews
and comments. For example, Dr Edward Norton, a member of the
Data Safety and Monitoring Committee for Berson 1993, published
his opinion that the data did not demonstrate a significant
beneficial eCect for vitamin A (Norton 1993). Similarly, Massof 2010
reviewed three RCTs, including Berson 1993 and Berson 2004a, and
concluded that the results did not prove that these interventions
slowed the rate of progression of RP.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Based on the results of four randomized controlled trials, there
is no clear evidence for the benefit of treatment with vitamin
A or docosahexaenoic acid (extracted from fish oil), or both, for
individuals with retinitis pigmentosa (RP), in terms of mean change
in visual field and electroretinogram amplitudes aSer one year, and
mean change in visual acuity at five years' follow-up. Consequently,
there is inadequate data at present to recommend the use of these
two interventions for individuals with RP. Although the exclusion
criteria across the included trials were extensive, thus limiting the
applicability of evidence to many individuals with RP, it is unlikely
that future trials would include patients that meet these criteria.
The findings from the trials included in this systematic review
should therefore be carefully considered in the management of
patients that meet these exclusion criteria.
Systemic side eCects or toxicity for long-term supplementation of
high-dose vitamin A is unknown.
Implications for research
The design and reporting of future trials on individuals with
RP should consider outcomes relevant to various stakeholders
(e.g. patients, physicians, and family members) as well as those
specified in this systematic review. Some of the included trials
included unplanned subgroup analysis that suggested diCerential
eCects based on previous vitamin A exposure, so investigators
should consider examining this issue in future randomized
controlled trials. Future trials on the eCects of vitamin A and fish
oils for RP should take into account the changes observed in
electroretinogram amplitudes and other outcome measures from
trials included in this review, in addition to previous cohort studies,
when calculating sample sizes in order to ensure adequate power
to detect clinically and statistically meaningful diCerence between
treatment arms.
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Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods • Study design: RCT, 2x2 factorial design
• Number randomized: 601 (vitamin A group = 146; trace group = 149; vitamin A + vitamin E group = 151;
vitamin E group = 155)
• Number analyzed: 572
• Enrollment period: May 1984 to June 1987
• Length of follow-up: planned = 4 years; actual = 4 years for all participants and 5.2 years for a propor-
tion of participants
• Sample size estimation: calculated sample size based on expected rate of decline in ERG amplitude
by 4% among participants taking supplements that would preserve a detectable ERG response for 5
additional years; 95% power
Participants • Country: USA and Canada
• Age (mean ± SD): vitamin A = 32.5 ± 0.7 years; trace = 32.2 ± 0.7 years; vitamin A + E = 32.3 ± 0.6 years;
vitamin E = 31.5 ± 0.6 years
• Sex: both men and women included (62% men and 38% women)
• Key inclusion criteria:
* Common forms of retinitis pigmentosa; participants aged 18 to 49 years; 1 study participant per
family
* Snellen visual acuity ≥ 20/100
* Visual field ≥ 8° diameter to V-4-e white test light on Goldmann perimeter
* 30 Hz ERG ≥ 0.12 μV or 0.5 Hz ERG ≥ 2.5 μV in at least 1 eye
* People with Usher's syndrome type 2 (i.e. RP with mild congenital deafness) were included
• Key exclusion criteria:
* Atypical forms of RP (including paravenous RP, clumped pigmentary retinal degeneration, sector
RP, or unilateral RP)
* Posterior subcapsular cataracts > 11% of the total lens area in both eyes
* X-linked carrier, Refsum disease, Bardet-Biedl syndrome, or Usher's syndrome type 1 (i.e. RP with
profound congenital deafness)
* RP associated with hereditary abetalipoproteinemia (i.e. Bassen-Kornzweig syndrome)
* Weight < the 5th percentile of weight for a given age, sex, and height
* Serum retinol level of ≥ 3.50 pmol/L (100 μg/dL), serum a-tocopherol levels > the normal range
adjusted for serum triglyceride level, total cholesterol level, and sex
* Total estimated intake of preformed vitamin A in diet plus pills > 11,500 IU/d
* Total estimated intake of vitamin E in diet plus pills > 40 IU/d
* Pregnancy, lactation
* Diseases affecting the absorption or metabolism of vitamins A or E
• Genetic profile
* Autosomal dominant - no. (%) vitamin A = 45 (31%); trace group = 40 (27%); vitamin A + E = 40
(26%); vitamin E = 40 (26%)
* Autosomal recessive- no. (%) vitamin A = 22 (15%); trace group = 22 (15%); vitamin A + E = 26
(17%); vitamin E = 29 (19%)
* X-linked no. (%) vitamin A = 15 (10%); trace group = 17 (11%); vitamin A + E = 12 (8%); vitamin E
= 12 (8%)
* Isolate no. (%) vitamin A = 59 (40%); trace group = 62 (42%); vitamin A + E = 62 (41%); vitamin E
= 63 (41%)
* Undetermined no. (%) vitamin A = 5 (3%); trace group = 8 (5%); vitamin A + E = 11 (7%); vitamin
E = 11 (7%)
Berson 1993 
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• Baseline clinical status: retinal arteriolar attenuation, elevated dark adaption thresholds, reduced
ERGs with delayed b wave implicit times. 94% had intraretinal pigment in the mid-peripheral fundus.
• Comparability of baseline characteristics: comparable
Interventions • Group A: vitamin A 15,000 IU/d, plus vitamin E 3 IU/d
• Trace group: vitamin A 75 IU/d, plus vitamin E 3 IU/d
• Group A + E: vitamin A 15,000 IU/d, plus vitamin E 400 IU/d
• Group E: vitamin A 75 IU/d, plus vitamin E 400 IU/d
• Vitamin A administered as retinyl palmitate and vitamin E as di-a-tocopherol in soS gelatin capsules
Outcomes • Primary outcome of the study: cone ERG response amplitudes to 30 Hz flicker stimulus
• Visual field assessed using Kinetic Goldmann perimeter
• Visual acuity assessed using transilluminated ETDRS charts at a distance of 3.2 m
• ERG: first, single flashes of white light (3.8 log foot-lamberts) presented every 2 seconds (i.e. 0.5 Hz
flashes) were used to elicit mixed cone-rod responses, then flashes of the same white light presented
at 30/second (30 Hz) were used to obtain cone-isolated responses. Responses to 0.5 Hz flashes were
summed as 2 waveforms of 32 responses each by the computer; amplitudes as low as 1 μ could be
detected. Responses to 30 Hz flashes of flickering light were recorded as 8 consecutive waveforms of
256 summations each. Responses to brief (10 μs in duration) full-field flashes of light were amplified,
and summed on a computer.
• Frequency outcomes assessed: at baseline, and annually for 4 to 6 years depending on the length of
follow-up
• Losses to follow-up: 29/601 (5%); 4 participants died, 25 declined to continue participation
• Adverse events: none reported
Notes • Funding sources: National Eye Institute, RP Foundation Fighting Blindness; vitamin capsules provided
by Hoffmann-LaRoche Inc, Nutley, NJ
• Statistical analyses: appropriate; factorial analysis of variance was used to evaluate main and inter-
action effects of vitamin A and E
• Subgroup analyses: post hoc analysis conducted in higher amplitude cohort (cohort of participants
with cone ERG > 0.68 μV (354 participants))
Notes: the trial was originally planned to allow for 4 years of follow-up for each participant. However,
due to slow recruitment (required 3 years), follow-up was continued on all participants until the last
randomized participants had completed their 4th year of follow-up. The DSMB recommended cessa-
tion of this protocol in September 1991 because by then all participants had completed their 4th year
of follow-up, and additional follow-up data would probably not lead to conclusions that would be sub-
stantially more precise. The smaller sample sizes at year 5 (n = 472) and year 6 (n = 261) reflect the fact
that the study was stopped after the last 4-year follow-up visit. The mean duration of follow-up was 5.2
years for all randomized participants.
Trial registration number: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “A separate set of randomization assignments was maintained for each stra-
tum based on a computer-generated set of random numbers to facilitate the
above randomization” (p 764)
Allocation concealment
(selection bias)
Low risk “Each bottle contained 100 capsules labeled with a lot number and instruc-
tions for storage at room temperature but not labeled as to content.” (p 763)
Blinding of Participants Low risk “Patients did not know the contents of the supplements under study or their
group assignment and also agreed not to know the course of their retinal de-
generation until the end of the study” (p 764)
Berson 1993  (Continued)
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Blinding of Caregivers Low risk “All members of the staC in contact with the patients, including the principal
investigator (E.L.B.), were masked as to the treatment group assignment of
each patient.” (p 764)
Blinding outcome asses-
sors for primary outcome
(visual field)
Low risk “All members of the staC in contact with the patients, were masked as to the
treatment group assignment of each patient. Each ocular examination and
ERG was performed without review of previous records” (p 764)
Blinding outcome asses-
sors for secondary out-
come (visual acuity)
Low risk “All members of the staC in contact with the patients were masked as to the
treatment group assignment of each patient. Each ocular examination and
ERG was performed without review of previous records” (p 764)
Blinding outcome asses-
sors for secondary out-
come (ERG)
Low risk “Each ocular examination and ERG was performed without review of previous
records.” (p 764)
Incomplete outcome data
addressed for primary out-
come (visual field)
Low risk “Only 5% (29/601) of patients failed to complete this study; four of these pa-
tients died and 25 patients declined to continue participation, most after the




Low risk “Only 5% (29/601) of patients failed to complete this study; four of these pa-
tients died and 25 patients declined to continue participation, most after the




Low risk “Only 5% (29/601) of patients failed to complete this study; four of these pa-
tients died and 25 patients declined to continue participation, most after the
fourth year.” (p 770)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement, as the study protocol is not
available





Methods • Study design: RCT, parallel design
• Number randomized: 221 (numbers of participants in each group were not specified)
• Number analyzed: 208 (DHA + vitamin A group = 105; control + vitamin A group = 103)
• Enrollment period: 1 year (13 May 1996 to 26 September 1997)
• Length of follow-up: planned = 4 years; actual = 4 years
• Sample size estimation: estimated that 220 participants were needed to provide sufficient power to
observe a statistically significant difference (29 dB) between mean change in the DHA + vitamin A and
control + vitamin A groups with respect to HFA 30-2 total point score over a 4-year interval and allowing
for 5% attrition; 90% power
Participants • Country: USA
• Age (mean ± SD): DHA + vitamin A = 37.8 ± 0.90 years; control + vitamin A = 36.0 ± 1.00 years
• Sex: both men and women included (49% women)
Berson 2004a 
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• Key inclusion criteria:
* Common forms of RP; participants aged 18 to 55 years; 1 study participant per family
* Snellen visual acuity ≥ 20/100
* HFA 30-2 program total point score ≥ 250 dB
* 30 Hz cone ERG amplitude of ≥ 0.68 uV in at least 1 eye
* Included participants with Usher's syndrome type 2 (i.e. RP with mild congenital deafness)
• Key exclusion criteria:
* Atypical forms of RP (including paravenous RP, clumped pigmentary retinal degeneration, sector
RP, or unilateral RP)
* Posterior subcapsular cataracts > 11% of the total lens area in both eyes
* X-linked carrier, Refsum disease, Bardet-Biedl syndrome, or Usher's syndrome type 1 (i.e. RP with
profound congenital deafness); RP associated with hereditary abetalipoproteinemia (i.e. Bassen-
Kornzweig syndrome)
* Weight < the 5th percentile of weight for a given age, sex, and height
* Serum retinol level of ≥ 3.50 pmol/L (100 μg/dL), serum cholesterol levels > 300 mg/dL total, total
estimated intake of preformed vitamin A in diet plus pills > 5000 IU/d, average or vitamin E intake
> 30 IU/d
* Pregnancy, lactation
* Diseases affecting the absorption or metabolism of vitamins A or DHA
• Genetic profile:
* Autosomal dominant - no. (%) DHA + vitamin A = 20 (19); control + vitamin A = 19 (18)
* Autosomal recessive- no. (%) DHA + vitamin A = 16 (15); control + vitamin A = 13 (13)
* X-linked no. (%) DHA + vitamin A = 5 (5); control + vitamin A = 8 (8)
* Isolate no. (%) DHA + vitamin A = 50 (48); control + vitamin A = 50 (49)
* Others no. (%) DHA + vitamin A = 8 (8); control + vitamin A = 9 (9)
• Baseline clinical status: retinal arteriolar attenuation, elevated dark adaption thresholds, reduced
ERGs with delayed b wave implicit times. 97% had intraretinal pigment in the mid-peripheral fundus.
50% of participants in the DHA + vitamin A group and 64% of participants in the control + vitamin A
group had cataracts in at least 1 eye at baseline. 11% of participants reported partial hearing loss.
• Comparability of baseline characteristics: comparable
Interventions • DHA + A group: 1200 mg/d DHA + 15,000 IU/d vitamin A
• Control + A group: 15,000 IU/d vitamin A
Each participant received either 6 capsules/day each containing 500 mg of fatty acids (200 mg of which
was DHA, for a total of 1200 mg/d of DHA), or 6 placebo capsules/day containing 500 mg of fatty acids
with no DHA, for 4 years. Vitamin A was administered as retinyl palmitate.
Outcomes • Primary outcome of the study: visual field - static perimetric sensitivity with the 30-2 program of the
HFA
• Visual field assessed using HFA size V target
• Visual acuity assessed using transilluminated ETDRS charts
• ERG: first, single flashes of white light (3.8 log foot-lamberts) presented every 2 seconds (i.e. 0.5 Hz
flashes) were used to elicit mixed cone-rod responses, then flashes of the same white light presented
at 30 per second (30 Hz) were used to obtain cone-isolated responses. Responses to 0.5 Hz flashes
were summed as 2 waveforms of 32 responses each by the computer; amplitudes as low as 1 μ could
be detected. Responses to 30 Hz flashes of flickering light were recorded as 8 consecutive waveforms
of 256 summations each. Responses to brief (10 μs in duration) full-field flashes of light were amplified,
and summed on a computer.
• Outcomes assessed at baseline, and annually for 4 years
• Losses to follow-up: 13/221 (5%); 1 participant died of breast cancer
• Adverse events: none reported
Notes • Funding sources: National Eye Institute, RP Foundation Fighting Blindness; vitamin capsules provided
by Martek
• Statistical analyses: appropriate; intention-to-treat analysis
Berson 2004a  (Continued)
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• Subgroup analyses: (post hoc) looked at subgroup of participants not taking vitamin A prior to enroll-
ment and those taking vitamin A for 2 years prior to enrollment in the trial
Trial registration number: not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "A separate set of randomization assignments was maintained for each stra-
tum based on a computer generated set of random numbers" (p 1299)
Allocation concealment
(selection bias)
Low risk ". . . computer generated set of random numbers that was available only to
a programmer who provided assignment information to the data manager
(C.W.D.) on a case-by-case basis. Group assignment was implemented by the
data manager" (p 1299)
Blinding of Participants Low risk "Patients did not know the contents of the supplement under study or their
treatment group assignment and also agreed not to know the course of their
retinal degeneration until the end of the study" (p 1299)
Blinding of Caregivers Low risk "All members of the staC in contact with the patients, including the principal
investigator (E.L.B.), were masked with regard to each patient’s treatment
group assignment" (p 1299)
Blinding outcome asses-
sors for primary outcome
(visual field)
Low risk "Each ocular examination was performed without review of previous record-
s" (p 1299)
Blinding outcome asses-
sors for secondary out-
come (visual acuity)
Low risk "Treatment group assignments and plasma DHA and RBC PE DHA levels were
placed in records separate from that used for ocular examinations as part of
masking those in contact with the patients" (p 1299)
Blinding outcome asses-
sors for secondary out-
come (ERG)
Low risk "Treatment group assignments and plasma DHA and RBC PE DHA levels were
placed in records separate from that used for ocular examinations as part of
masking those in contact with the patients" (p 1299)
Incomplete outcome data
addressed for primary out-
come (visual field)
Low risk "Two hundred eight of these patients (221) completed all 4 annual follow-up
visits. Analyses performed on patients with partial follow-up, but with missing
values leS as missing and after using multiple imputation methods to account




Low risk "Two hundred eight of these patients (221) completed all 4 annual follow-up
visits. Analyses performed on patients with partial follow-up, but with missing
values leS as missing and after using multiple imputation methods to account




Low risk "Two hundred eight of these patients (221) completed all 4 annual follow-up
visits. Analyses performed on patients with partial follow-up, but with missing
values leS as missing and after using multiple imputation methods to account
for missing data among patients with incomplete followup" (p 1301)
Selective reporting (re-
porting bias)
Unclear risk Study protocol is not available.
Other bias Low risk We did not detect other bias.
Berson 2004a  (Continued)
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Study characteristics
Methods • Study design: RCT, parallel design
• Number randomized: 44 (DHA group = 23; control (placebo) group = 21)
• Number analyzed: 41 (numbers of participants in each group were not specified)
• Enrollment period: 20 February 1995
• Length of follow-up: planned = 4 years; actual = 4 years
• Sample size estimation: derived from a predicted decrease of 0.085 log units/year in cone 31 Hz flicker
amplitude for the placebo group, assuming a change of 0.34 log units over 4 years in the placebo group
and that reducing the rate of progression by 40% is meaningful for a 2-sided test with a.05 significance
level and a power of 80%
Participants • Country: USA
• Age (mean ± SD): 16 ± 9 years; age range 4 to 38 years
• Sex: males only
• Key inclusion criteria:
* RP diagnosed by an ophthalmologist specializing in retinal disease
* History that was not only consistent with X-linked inheritance, but that also ruled out dominant
or recessive RP
* HFA 30-2 program total point score ≥ 250 dB
* 31 Hz cone ERG amplitude of ≥ 0.68 μV in at least 1 eye
* No excessive dietary intake of fish or supplementation with fish oil
• Key exclusion criteria:
* Female
* Genetic profile: X-linked RP gene mutations (retinitis pigmentosa GTPase regulator (RPGR), retinitis
pigmentosa 24 (X-linked recessive) (RP24))
• Baseline clinical status: not reported
• Comparability of baseline characteristics: comparable
Interventions • Intervention 1: DHA group = 400 mg/d
• Intervention 2: placebo group = corn/soy oil triglyceride
Each participant received 2 capsules/day each containing 500 mg of fatty acids (200 mg of which was
DHA, for a total of 400 mg/d of DHA), or 2 placebo capsules/day containing 500 mg of fatty acids with
no DHA, administered for 4 years.
Outcomes • Primary outcome of the study: cone ERG (31 Hz electroretinogram amplitude)
• Visual field assessed using HFA size V target
• Visual acuity assessed using transilluminated ETDRS charts
• ERG: 30 Hz electroretinogram amplitude
• Outcomes assessed at baseline, and annually for 4 years
• Losses to follow-up: 3/44 (6%) in total: 2 in the placebo group and 1 in the intervention group
• Adverse events: none reported
Notes • Funding sources: National Eye Institute, Orphan Products Development program of the US Food and
Drug Administration, and the RP Foundation Fighting Blindness; capsules provided by Martek
• Statistical analyses: appropriate; intention-to-treat analysis
• Subgroup analyses: rod ERG in children < 12 years and children ≥ 12 years
Trial registration number: not reported
Risk of bias
Ho>man 2004 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk “Placebo and + DHA assignments were made following a block randomization
schedule (10/block).” (p 705)
Method used for random sequence generation is unclear.
Allocation concealment
(selection bias)
Low risk “Relatives were randomized together to eliminate a potential for mixing of
capsules; there were five sib-pairs in each cohort” (p 705)
Blinding of Participants Low risk “All medications were labeled either A or B by the manufacturer. Both study
oils were encapsulated with ethyl vanillin-flavored gelatin; thus, smell and
taste of the capsules were identical.” (p 705)
Blinding of Caregivers Low risk “Martek retained the code and divulged group assignment to the Data and
Safety Monitoring Committee when requested to or to a patient’s physician in
case of a medical emergency.” (p 705)
Blinding outcome asses-
sors for primary outcome
(visual field)
Low risk “The randomization code was not available to study personnel conducting vi-
sual function assessments until after completion of testing.” (p 705)
Blinding outcome asses-
sors for secondary out-
come (visual acuity)
Low risk “The randomization code was not available to study personnel conducting vi-
sual function assessments until after completion of testing.” (p 705)
Blinding outcome asses-
sors for secondary out-
come (ERG)
Low risk “The randomization code was not available to study personnel conducting vi-
sual function assessments until after completion of testing.” (p 705)
Incomplete outcome data
addressed for primary out-
come (visual field)
Low risk “Of the 44 patients enrolled, all completed 3 years; 41 patients completed 4
years. . . test results from the previous year were used in place of an occasional




Low risk “Of the 44 patients enrolled, all completed 3 years; 41 patients completed 4
years. . . test results from the previous year were used in place of an occasional




Low risk “Of the 44 patients enrolled, all completed 3 years; 41 patients completed 4
years. . . test results from the previous year were used in place of an occasional
missing value” (pp 706, 709)
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement as the study protocol is not avail-
able





Methods • Study design: RCT, parallel design
• Number randomized: 78 (DHA group = 41; placebo group = 37)
• Number analyzed: 60 (DHA group = 33; placebo group = 27)
• Enrollment period: 5 August 2005 to 1 June 2008
Ho>man 2014 
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• Length of follow-up: planned = 4 years; actual = 4 years
• Sample size estimation: "The estimated mean (SE) rate of decline in cone ERG function in XLRP in the
absence of treatment (ie, event rate) was 0.065 (0.007) log μV/y. Assuming a treatment effect of 40%,
statistical significance for a 2-sided test using a significance level of.05 and 80% power would require
24 participants per group."
Participants • Country: USA and Canada
• Age (mean ± SE): DHA = 16.1 ± 1.4 years; placebo = 14.9 ± 1.1 years
• Sex: males only
• Key inclusion criteria:
* Age between 7 to 32 years
* Male sex; diagnosis of RP by a retinal specialist
* Clinical diagnosis consistent with X-linked inheritance
* Enrolling minors and young adults (early onset of X-linked disease; ages 7 to 32)
* Measurable cone ERG responses; patients with less than 0.64 microvolt response to 31 Hz flicker
will be excluded as they are more likely to become undetectable during the study
* Both eyes must meet entry criteria as both will be tested (i.e. no cataracts requiring surgery or reti-
nal detachments)
* Media clarity sufficient for fundus photography
* Able to return to study site at yearly intervals
* Willing to supply blood samples at 6-month intervals
* Judiciously take the placebo or DHA supplement for the 4-year study duration
* Patient/parent/guardian understands and signs consent form
• Key exclusion criteria:
* Excessive fish consumption (e.g. cold-water fish such as salmon, tuna, sardines) and/or fish oil sup-
plementation (or other oil containing DHA)
* Baseline RBC DHA levels showing evidence of supplementation (a typical level of RBC DHA in nor-
mals is about 3.8%)
* Chronic metabolic disease that may interfere with fatty acid metabolism or require anticoagulant
medication
• Genetic profile:
• X-linked no. (%) DHA = 41 (100%); placebo = 37 (100%)
• Baseline clinical status: "anthropometric, blood chemistry, ERG, and ancillary ocular characteristics
at baseline were similar between groups with the exception of poorer visual field sensitivities in the
DHA group"
• Comparability of baseline characteristics: participants in the DHA group were slightly older than those
in the placebo group and had marginally higher RBC DHA levels
Interventions • DHA group: 500-milligram gelatin capsules containing 200 mg of algal-derived DHA; dose of 3 to 18
capsules per day to achieve a dosage of 30 mg/kg/d. The total amount of fat (oil) ranged from 1.5 to
9 g/d, and the total DHA dosage ranged from 600 to 3600 mg/d.
• Placebo group: 500-milligram gelatin capsules containing 200 mg of corn/soy (placebo) triglycerides;
dosage of 30 mg/kg/d
Outcomes • Primary outcome of the study: cone ERG (31 Hz electroretinogram amplitude)
• Rod amplitudes and maximal ERG amplitudes elicited from the dark-adapted eye
• Cone b-wave implicit times derived from the time between a test flash and corresponding b-wave peak
• ERG: 30 Hz electroretinogram amplitude
• Visual acuity
• Final dark-adapted threshold
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• Total VFS
• Ellipsoid zone transitional sensitivity
• Outcomes assessed at baseline, and annually for 4 years
• Losses to follow-up: 24 (31%); 13 in the placebo group (1 due to apathy, 1 due to seeing white circles,
2 due to lost contact, 2 due to parents being too busy to travel to Dallas, 1 due to depression from
continued vision loss, 1 due to floaters and increased sensitivity to light, 1 moved to Iraq, 2 due to
apathy, 1 ran away from home, and 1 due to being “terribly sick and sore when taking capsules”); 11 in
the intervention group (4 lost to follow-up, 2 due to apathy, 1 due to apathy and difficulty in traveling
to Dallas, 1 changed mind about participating and consumed no capsules, 1 due to inconsistent bowel
movements, 1 due to dehydration and fatigue, 1 due to capsules possibly exacerbating inflammatory
bowel disease)
• Adverse events: "Twenty seven participants had a total of 42 related or possibly related TEAEs (22 in
the DHA group and 20 in the placebo group). Self-reported and blood chemistry TEAEs were sporadic
with no identifiable trends; the exception was 1 participant with a family history of Crohn disease who
was sensitive to DHA supplementation. No severe TEAEs requiring hospitalization were reported in
the 4-year trial interval."
Notes • Funding sources: Orphan Products Development program of the US Food and Drug Administration
(grant 5RO1FD002543), Foundation Fighting Blindness (grant C-TX02-0704-0274); DSM Nutritional
Products provided DHA and placebo capsules gratis
• Statistical analyses: modified intention-to-treat analysis
• Subgroup analyses: total VFS in participants < 14 years and participants ≥ 14 years
Trial registration number: NCT00100230
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Participants (ages 7–31 years) meeting entry criteria were assigned to DHA (n
= 41) or placebo (n = 37) using a computer-generated randomization schedule
with varying block sizes" (p 4)
Allocation concealment
(selection bias)
Unclear risk Insufficient information to permit judgement
Blinding of Participants Low risk "The DHA and placebo capsules were indistinguishable based on appearance,
smell, or taste and contained vitamins E and C as antioxidants (12.5 mg each)
and food-grade orange extract as flavoring (5.9 mg)." (p 4)
Blinding of Caregivers Low risk "All testing personnel were masked to treatment assignment."; "The DHA and
placebo capsules were indistinguishable based on appearance, smell, or taste
and contained vitamins E and C as antioxidants (12.5 mg each) and food-grade
orange extract as flavoring (5.9 mg)." (p 4)
Blinding outcome asses-
sors for primary outcome
(visual field)
Low risk "All testing personnel were masked to treatment assignment." (p 4)
Blinding outcome asses-
sors for secondary out-
come (visual acuity)
Low risk "All testing personnel were masked to treatment assignment." (p 4)
Blinding outcome asses-
sors for secondary out-
come (ERG)
Low risk "All testing personnel were masked to treatment assignment." (p 4)
Ho>man 2014  (Continued)
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Incomplete outcome data
addressed for primary out-
come (visual field)
High risk 22 of 37 participants in placebo group and 29 of 41 participants in the DHA
group completed 4-year follow-up; attrition and reasons for attrition were de-
scribed; "A lower than expected event rate and an underpowered trial due to




High risk 22 of 37 participants in placebo group and 29 of 41 participants in the DHA
group completed 4-year follow-up; attrition and reasons for attrition were de-
scribed; "A lower than expected event rate and an underpowered trial due to




High risk 22 of 37 participants in placebo group and 29 of 41 participants in the DHA
group completed 4-year follow-up; attrition and reasons for attrition were de-
scribed; "A lower than expected event rate and an underpowered trial due to
participant dropout were primary trial limitations." (p 9)
Selective reporting (re-
porting bias)
High risk Third outcome listed in the ClinicalTrials.gov registration (loss of peripheral vi-
sual fields) was not described in the publication.
Other bias Low risk We did not detect other bias.
Ho>man 2014  (Continued)
±: plus or minus/with or without
>: more/greater than
≥: more/greater than or equal to
<: less than
DHA: docosahexaenoic acid
DSMB: Data and Safety Monitoring Board
EDTRS: Early Treatment Diabetic Retinopathy Study
ERG: electroretinogram
HFA: Humphrey Field Analyzer
IU: international units
no.: number
RBC: red blood cells




TEAEs: treatment-emergent adverse events
VFS: visual field sensitivity
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bergsma 1977 Not randomized. A cohort of RP patients followed prospectively before and after administration of
vitamin A without a control group.
Berson 2010 Vitamin A was given to all participants. Not able to justify the effectiveness of vitamin A
Berson 2012 Re-analysis of 3 RCTs
Dagnelie 2000 Not randomized. A cohort of RP patients and patients with related retinal degenerations followed
prospectively before and after administration of lutein. No control group
Fex 1996 Uncontrolled trial, did not examine the outcome of interest to this review
Johnson 2008 Not the population of interest, healthy women not retinitis pigmentosa
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Study Reason for exclusion
JPRN UMIN000005510 Single-arm study
Massof 2010 Not an RCT, letter
McCafferty 2017 Not the population of interest
NCT00004345 Not an RCT




NCT02018692 Not a comparator of interest
Norton 1993 Not a comparator of interest
Pierce 2017 Re-analysis of 3 RCTs
Sibulesky 1999 Secondary analysis assessing the safety of long-term vitamin A supplementation for RP in an RCT
(Berson 1993)
Tcherkes 1950 Not randomized. A cohort of RP patients followed prospectively before and after administration of
vitamin A. No control group
Wheaton 2003 Secondary analysis assessing the safety of long-term DHA supplementation for X-linked RP in an
RCT
Wittes 2011 Not an RCT, letter
Zhao 2019 Not an RCT, review article
DHA: docosahexaenoic acid
RCT: randomized controlled trial
RP: retinitis pigmentosa
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name A Ayurvedic treatment of retinitis pigmentosa compared with modern treatment
Methods Randomized parallel-group design
Participants Inclusion criteria: individuals aged 16 to 50 years, who are: willing to participant in the present
study; show symptoms of night blindness, markedly reduced dark adaptation, progressive visual
field loss, double vision, etc.; have bony corpuscles, have fundus retinal vessels narrowing espe-
cially arteriolar narrowing; have vitreous changes such as cells, opacities and pigments; macular
changes; such as edema atrophic changes, pigment clumping, etc.
Exclusion criteria: individuals aged age < 16 or > 50 years, individuals not willing for present study,
or are extremely debilitating and not able to withstand treatment procedures, or have vision less
CTRI/2016/01/006497 
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than 6/60 or any lenticular changes, individuals with total blindness and other known systemic
pathology will be excluded from study.
Interventions Intervention 1: 1) Snehayukta Virechana, followed by 2) oral medication along with nasya and
tarpana
Intervention 2: 1) Snehayukta Virechana include, deepana and pachana by trikatu churna for 3 to
5 days, snehapana by plain cow ghrita till the samyak Snigdha Lakshana appear, external snehana
with bala taila followed by swedana once a day for 3 days, virechana with triphala kwath and eran-
da taila samsarjana Krama for 3 to 7 days. (Acc. to type of Shuddhi), followed by 2) bhrinaraja taila
Nasya 7 days → tarpana with goghrita for 7 days. 1 such course of nasya and tarpana in a month for
3 months. 3) The oral medicine will be started after samsarjana krama till completion of the thera-
py.
Comparator intervention: 1) capsule Aquasol A (vitamin A) 50,000 IU once daily for 1 month 2)
tablet Complamina retard once daily for 3 months
Outcomes Primary outcomes:
• Dark adaptation visual acuity test by self-illuminating Snellen’s chart drum
• Reduction in dioptric power of glasses by refraction
• Automated perimetry—for retinal sensitivity change and field of vision
• Fixed white on white or white on red stimulus will be used during perimetry
• Fundus photographic change
Secondary outcome:
• Delay or check in the progression of night blindness, dark adaptation, diplopia, reduced periph-
eral vision
Maximum follow-up: 6 months
Starting date February 2015






Study name Study of docosahexaenoic acid (DHA) supplementation in patients with X-linked retinitis pigmen-
tosa
Methods Randomized parallel-group design
Participants Inclusion criteria: 46 children and adults with early stage X-linked retinitis pigmentosa, with suf-
ficient cone function determined by recordable ERG (30 Hz amplitude; greater than 0.32 micro-
volts); visual fields greater than 20 degrees; sufficient rod function (greater than 3.0 microvolts am-
plitude); media clarity sufficient for fundus photography; with no concurrent use of anticoagulant
medication; no chronic metabolic disease that could interfere with fatty acid metabolism; and no
bleeding of clinical significance
Exclusion criteria: not reported
Interventions Intervention: 2 gel capsules per day of docosahexaenoic acid (DHA)-enriched oil
NCT00004827 
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Comparator intervention: 2 gel capsules per day of placebo
Outcomes Primary outcome: retardation of progression of visual function loss
Secondary outcome: not reported
Maximum follow-up: 3 years
Starting date March 1996








A D D I T I O N A L   T A B L E S
 
Study ID Berson 1993 Berson 2004a Hoffman 2004 Hoffman 2014
Design 2x2 factorial design Parallel Parallel Parallel
Autosomal dominant Autosomal dominant Not included Not included
Autosomal recessive Autosomal recessive Not included Not included
X-linked X-linked X-linked X-linked
Dominant with mutation Dominant with mutation Not included Not included





Undetermined Undetermined Not included Not included










601 221 44 78
Interven-
tion(s)
Vitamin A + vitamin E
trace = 146
Vitamin A + vitamin E =
151
Vitamin A trace + vitamin
E trace =149
DHA + vitamin A = 105 (number
analyzed)






DHA placebo = 37
Table 1.   Summary of included trials 
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Vitamin A trace + vitamin
E = 155
Dose Vitamin A = 15,000 IU/d
Vitamin A trace = 75 IU/d
Vitamin E = 400 IU/d
Vitamin E trace = 3 IU/d
DHA, 1200 mg/d
Vitamin A, 1500 IU/d











Rod ERG, visual acuity,
visual field
Cone ERG, visual acuity, visual







Rod and maximal ERG ampli-
tudes, cone ERG implicit times,
visual acuity, final dark-adapted
threshold, shape discrimination
threshold, foveal VFS, macular
VFS, peripheral VFS, total VFS,




4 to 6 years 4 years 4 years 4 years
Table 1.   Summary of included trials  (Continued)
DHA: docosahexaenoic acid
ERG: electroretinogram
HFA: Humphrey Field Analyzer
IU: international units










(V-4-e white test light)
HFA 30-2 program 640 HFA, program 30-2 640 HFA, program 30-2;
program 30/60-2 was
used for participants
with fields > 30 degrees
Effect
measure




of loss of field sen-
sitivity
Mean change in defect
in
Humphrey spot size III
field from baseline at 4
years
Annual rate of change in
foveal, macular, periph-
eral, and total visual field


















Vitamin A + vitamin E
trace = 5.6%
Vitamin A + vitamin E =
6.2%
DHA + vitamin A
= 36.95 ± 3.36 dB/
year
DHA = 2.4 ± 3.66 dB
(0.24 logMAR)
Placebo = 1.4 ± 1.32 dB
(0.14 logMAR)
Mean change ± SE
Foveal VFS:
DHA = −0.02 ± 0.05
Table 2.   Summary of analysis of visual outcomes (visual field and visual acuity) in included trials 
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Vitamin A trace +
vitamin E trace = 5.9%
Vitamin A trace +
vitamin E = 6.3%
Control + vitamin
A = 37.68 ± 3.36
dB/year
Placebo = −0.47 ± 0.03
Macular VFS:
DHA = −0.42 ± 0.05
Placebo = −0.85 ± 0.03
Peripheral VFS:
DHA = −0.39 ± 0.02
Placebo = −0.86 ± 0.02
Total VFS:
DHA = −0.39 ± 0.02




No significant vitamin A












ETDRS chart ETDRS chart ETDRS chart Electronic ETDRS
Effect
measure
Number of ETDRS letters
lost per year








between years 0 and 4
for the average of both
eyes
Annual rate of change in
letters correct between
years 0 and 4 for the av-










Mean change from log-
MAR baseline visual
acuity




Vitamin A + vitamin E
trace = 1.1 letters/year
Vitamin A + vitamin E =
0.7 letters/year
Vitamin A trace +
vitamin E trace = 0.9
letters/year
Vitamin A trace +
vitamin E = 0.9
letters/year





0.68 + 0.12 let-
ters/year
DHA = 0.05 ± 0.23 log
units (logMAR)
Placebo = 0.06 ± 0.2
log
units (logMAR)
DHA = −0.8 ± 0.8












Table 2.   Summary of analysis of visual outcomes (visual field and visual acuity) in included trials  (Continued)
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa (Review)









Cochrane Database of Systematic Reviews
DHA: docosahexaenoic acid
ETDRS: Early Treatment Diabetic Retinopathy Study
HFA: Humphrey Field Analyzer
RCT: randomized controlled trial
VFS: visual field sensitivity
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  Berson 1993 Berson 2004a Hoffman 2004 Hoffman 2014
Rate of decline of re-
maining 30 Hz ERG
amplitude per year
Vitamin A + vitamin E
trace = 6.1%
Vitamin A + vitamin E
= 6.3%
Vitamin A trace + vit-
amin E trace = 7.1%
Vitamin A trace + vit-




















DHA = −0.199 ± 0.172
log μV









DHA = −0.028 ± 0.001
log μV
Placebo = −0.022 ±
0.002 log μV
DHA = −0.94 ± 1.00 μV
Placebo = −0.95 ±
1.00 μV
Percentage of partic-
ipants with less than
50% decline in 30 Hz
ERG amplitude rel-
ative to baseline at
year 6 (high ampli-
tude cohort)
Vitamin A + vitamin E
trace = 62%
Vitamin A + vitamin E
= 50%
Vitamin A trace + vit-
amin E trace = 48%
Vitamin A trace + vit-



























a significant main ef-
fect of year(<.0001),
with the population
as a whole showing
significant progres-
sion. The main ef-












DHA = −0.010 ± 0.001
log μV
Placebo = −0.023 ±
0.001 log μV
DHA = −0.98 ± 1.00 μV



















DHA = −0.042 ± 0.001
log μV
Placebo = −0.036 ±
0.001 log μV
DHA = −0.91 ± 1.00 μV









Subtracting the mean baseline





















































































































































The vitamin A group had, on average, a slow-
er rate of decline of retinal function than the 2
groups not receiving this dosage.
No significant difference No significant difference No significant difference
Table 3.   Summary of analysis of electroretinogram in included studies  (Continued)
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Retinitis Pigmentosa] explode all trees
#2 (retini* or retina* or retinopath*) near pigment*
#3 ((tapetoretina* or tapeto retina*) near (degener* or dystroph*))
#4 rod near cone near dystroph*
#5 MeSH descriptor: [Tangier Disease] explode all trees
#6 tangier near disease*
#7 {or #1-#6}
#8 MeSH descriptor: [Vitamin A] explode all trees
#9 "vitamin a" or "aquasol a" or "vitamin a1" or "a vitamin" or "vit a" or "A 313" or "all-trans-retinyl alcohol" or "Anti-Infective Vitamin" or
"Antixerophthalmic Vitamin" or "Arovit" or "Avibon" or "Avitol" or "Axerol" or "Axerophthol" or "Axerophtholum" or "Biosterol" or "Biovit-A"
or "Chocola A" or "Del-VI-A" or "Ido A 50" or "Idrurto A" or "Lard Factor" or "Ledovit A" or "Micelle A" or "Mulsal A Megadosis" or "Oleovitamin
A" or "Ophthalamin" or "Palmitate-1-14C" or "Rinocusi Vitaminico" or "viatmin a" or "VitaminoSalmina" or "Vitaminum A" or "Viva-Drops"
or "Vogan"
#10 MeSH descriptor: [Retinoids] explode all trees
#11 retino* or retinyl palmitate*
#12 MeSH descriptor: [beta Carotene] explode all trees
#13 beta carotene* or betacarotene* or Carotaben or "Max Caro" or MaxCaro or Solatene or Vetoron or BellaCarotin or Provatene or "b-tene"
or "beta carotin" or betatene or lurotin or solvin or "b Carotene" or "B-Caro-T" or BETACRTN or Caroguard or Lumitene or "Provitamin A"
#14 MeSH descriptor: [Fish Oils] explode all trees
#15 (oil* near (fish* or "cod liver" or halibut or squid or krill or mackerel or menhaden or salmon or seal or "shark liver" or seafood))
#16 EPA or EFA or MaxEPA or ameu or efamed or epax or feniko or himega or "k 85" or "lachs 550" or lipitac or olemar or optimepa or pikasol
or promega or superepa or "sea omega"
#17 MeSH descriptor: [Fatty Acids, Omega-3] explode all trees
#18 omega3 or "omega 3" or n3 fatty acid* or n 3 fatty acid* or "n3 PUFA" or "n 3 PUFA" or n3 polyunsaturated fatty acid* or n 3
polyunsaturated fatty acid* or n3 Oil* or n 3 oil* or "bilantin omega" or "conchol 36" or "eicosa e" or eicosapen or epaisdin or epanova
or "omega forte" or sakana
#19 MeSH descriptor: [Docosahexaenoic Acids] explode all trees
#20 docosahex* or dhasco or DHA or DPA
#21 MeSH descriptor: [Eicosapentaenoic Acid] explode all trees
#22 eicosapen* or timnodonic or icosapent*
#23 {or #8-#22}
#24 #7 and #23
Appendix 2. MEDLINE Ovid search strategy
1. Randomized Controlled Trial.pt.
2. Controlled Clinical Trial.pt.






9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. exp animals/ not humans.sh.
11. 9 not 10
12. exp Retinitis Pigmentosa/
13. ((retini* or retina* or retinopath*) adj2 pigment*).tw.
14. ((tapetoretina* or tapeto retina*) adj2 (degener* or dystroph*)).tw.
15. (rod adj2 cone adj2 dystroph*).tw.
16. exp Tangier Disease/
17. (tangier adj2 disease*).tw.
18. or/12-17
19. exp Vitamin A/
20. ("vitamin a" or "aquasol a" or "vitamin a1" or "a vitamin" or "vit a" or "A 313" or "all-trans-retinyl alcohol" or "Anti-Infective Vitamin" or
"Antixerophthalmic Vitamin" or "Arovit" or "Avibon" or "Avitol" or "Axerol" or "Axerophthol" or "Axerophtholum" or "Biosterol" or "Biovit-A"
or "Chocola A" or "Del-VI-A" or "Ido A 50" or "Idrurto A" or "Lard Factor" or "Ledovit A" or "Micelle A" or "Mulsal A Megadosis" or "Oleovitamin
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A" or "Ophthalamin" or "Palmitate-1-14C" or "Rinocusi Vitaminico" or "viatmin a" or "VitaminoSalmina" or "Vitaminum A" or "Viva-Drops"
or "Vogan").tw.
21. exp Retinoids/
22. (retino* or retinyl palmitate*).tw.
23. exp beta Carotene/
24. (beta carotene* or betacarotene* or Carotaben or "Max Caro" or MaxCaro or Solatene or Vetoron or BellaCarotin or Provatene or "b-
tene" or "beta carotin" or betatene or lurotin or solvin or "b Carotene" or "B-Caro-T" or BETACRTN or Caroguard or Lumitene or "Provitamin
A").tw.
25. exp Fish Oils/
26. (oil* adj3 (fish* or "cod liver" or halibut or squid or krill or mackerel or menhaden or salmon or seal or "shark liver" or seafood)).tw.
27. (EPA or EFA or MaxEPA or ameu or efamed or epax or feniko or himega or "k 85" or "lachs 550" or lipitac or olemar or optimepa or pikasol
or promega or superepa or "sea omega").tw.
28. exp Fatty Acids, Omega-3/
29. (omega3 or "omega 3" or n3 fatty acid* or n 3 fatty acid* or "n3 PUFA" or "n 3 PUFA" or n3 polyunsaturated fatty acid* or n 3
polyunsaturated fatty acid* or n3 Oil* or n 3 oil* or "bilantin omega" or "conchol 36" or "eicosa e" or eicosapen or epaisdin or epanova
or "omega forte" or sakana).tw.
30. exp Docosahexaenoic Acids/
31. (docosahex* or dhasco or DHA or DPA).tw.
32. exp Eicosapentaenoic Acid/
33. (eicosapen* or timnodonic or icosapent*).tw.
34. or/19-33
35. 18 and 34
36. 11 and 35
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase.com search strategy
#1 'randomized controlled trial'/exp
#2 'randomization'/exp
#3 'double blind procedure'/exp
#4 'single blind procedure'/exp
#5 random*:ab,ti
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 'animal'/exp OR 'animal experiment'/exp
#8 'human'/exp
#9 #7 AND #8
#10 #7 NOT #9
#11 #6 NOT #10
#12 'clinical trial'/exp
#13 (clin* NEAR/3 trial*):ab,ti







#21 'latin square design'/exp
#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21
#23 #22 NOT #10




#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti
#29 #25 OR #26 OR #27 OR #28
#30 #29 NOT #10
#31 #30 NOT (#11 OR #23)
#32 #11 OR #24 OR #31
#33 'retinitis pigmentosa'/exp
#34 ((retini* OR retina* OR retinopath*) NEAR/2 pigment*):ab,ti
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#35 ((tapetoretina* OR 'tapeto retina*') NEAR/2 (degener* OR dystroph*)):ab,ti
#36 (rod NEAR/2 cone NEAR/2 dystroph*):ab,ti
#37 'tangier disease'/exp
#38 (tangier NEAR/2 disease*):ab,ti
#39 #33 OR #34 OR #35 OR #36 OR #37 OR #38
#40 'retinol'/exp
#41 ("vitamin a" OR "aquasol a" OR "vitamin a1" OR "a vitamin" OR "vit a" OR "A 313" OR "all-trans-retinyl alcohol" OR "Anti-Infective
Vitamin" OR "Antixerophthalmic Vitamin" OR "Arovit" OR "Avibon" OR "Avitol" OR "Axerol" OR "Axerophthol" OR "Axerophtholum" OR
"Biosterol" OR "Biovit-A" OR "Chocola A" OR "Del-VI-A" OR "Ido A 50" OR "Idrurto A" OR "Lard Factor" OR "Ledovit A" OR "Micelle A"
OR "Mulsal A Megadosis" OR "Oleovitamin A" OR "Ophthalamin" OR "Palmitate-1-14C" OR "Rinocusi Vitaminico" OR "viatmin a" OR
"VitaminoSalmina" OR "Vitaminum A" OR "Viva-Drops" OR "Vogan"):ab,ti,tn
#42 'retinoid'/exp
#43 retino*:ab,ti,tn OR 'retinyl palmitate*':ab,ti,tn
#44 'beta carotene'/exp
#45 'beta carotene*':ab,ti,tn OR betacarotene*:ab,ti,tn OR carotaben:ab,ti,tn OR 'max caro':ab,ti,tn OR maxcaro:ab,ti,tn OR solatene:ab,ti,tn
OR vetoron:ab,ti,tn OR 'bellacarotin':ab,ti,tn OR provatene:ab,ti,tn OR 'b-tene':ab,ti,tn OR 'beta carotin':ab,ti,tn OR betatene:ab,ti,tn
OR lurotin:ab,ti,tn OR solvin:ab,ti,tn OR "b Carotene":ab,ti,tn OR "B-Caro-T":ab,ti,tn OR BETACRTN:ab,ti,tn OR Caroguard:ab,ti,tn OR
Lumitene:ab,ti,tn OR "Provitamin A":ab,ti,tn)
#46 'fish oil'/exp
#47 (oil* NEAR/3 (fish* OR 'cod liver*' OR halibut OR squid OR krill OR mackerel OR menhaden OR salmon OR seal OR 'shark liver*' OR
seafood)):ab,ti,tn
#48 epa:ab,ti,tn OR efa:ab,ti,tn OR maxepa:ab,ti,tn OR ameu:ab,ti,tn OR efamed:ab,ti,tn OR epax:ab,ti,tn OR feniko:ab,ti,tn OR
himega:ab,ti,tn OR 'k 85':ab,ti,tn OR 'lachs 550':ab,ti,tn OR lipitac:ab,ti,tn OR olemar:ab,ti,tn OR optimepa:ab,ti,tn OR pikasol:ab,ti,tn OR
promega:ab,ti,tn OR superepa:ab,ti,tn OR "sea omega":ab,ti,tn
#49 'omega 3 fatty acid'/exp
#50 omega3:ab,ti,tn OR 'omega 3':ab,ti,tn OR 'n3 fatty acid*':ab,ti,tn OR 'n 3 fatty acid*':ab,ti,tn OR 'n3 pufa':ab,ti,tn OR 'n 3 pufa':ab,ti,tn
OR 'n3 polyunsaturated fatty acid*':ab,ti,tn OR 'n 3 polyunsaturated fatty acid*':ab,ti,tn OR 'n3 oil*':ab,ti,tn OR 'n 3 oil*':ab,ti,tn OR 'bilantin
omega':ab,ti,tn OR 'conchol 36':ab,ti,tn OR 'eicosa e':ab,ti,tn OR eicosapen:ab,ti,tn OR epaisdin:ab,ti,tn OR epanova:ab,ti,tn OR 'omega
forte':ab,ti,tn OR sakana:ab,ti,tn
#51 'docosahexaenoic acid'/exp
#52 docosahex*:ab,ti,tn OR dhasco:ab,ti,tn OR dha:ab,ti,tn OR dpa:ab,ti,tn
#53 'icosapentaenoic acid'/exp
#54 eicosapen*:ab,ti,tn OR timnodonic:ab,ti,tn OR icosapent*:ab,ti,tn
#55 #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54
#56 #39 AND #55
#57 #32 AND #56
Appendix 4. PubMed search strategy
1. ((randomized controlled trial[pt]) OR (controlled clinical trial[pt]) OR (randomised[tiab] OR randomized[tiab]) OR (placebo[tiab]) OR
(drug therapy[sh]) OR (randomly[tiab]) OR (trial[tiab]) OR (groups[tiab])) NOT (animals[mh] NOT humans[mh])
2. ((retini*[tw] OR retina*[tw] OR retinopath*[tw]) AND pigment*[tw])
3. (tapetoretina*[tw] OR tapeto retina*[tw]) AND (degener*[tw] OR dystroph*[tw])
4. (rod[tw] AND cone[tw] AND dystroph*[tw])
5. (tangier[tw] AND disease*[tw])
6. #2 OR #3 OR #4 OR #5
7. "vitamin a"[tw] OR "aquasol a"[tw] OR "vitamin a1"[tw] OR "a vitamin"[tw] OR "vit a"[tw] OR "A 313"[tw] OR "all-trans-retinyl
alcohol"[tw] OR "Anti-Infective Vitamin"[tw] OR "Antixerophthalmic Vitamin"[tw] OR "Arovit"[tw] OR "Avibon"[tw] OR "Avitol"[tw] OR
"Axerol"[tw] OR "Axerophthol"[tw] OR "Axerophtholum"[tw] OR "Biosterol"[tw] OR "Biovit-A"[tw] OR "Chocola A"[tw] OR "Del-VI-A"[tw] OR
"Ido A 50"[tw] OR "Idrurto A"[tw] OR "Lard Factor"[tw] OR "Ledovit A"[tw] OR "Micelle A"[tw] OR "Mulsal A Megadosis"[tw] OR "Oleovitamin
A"[tw] OR "Ophthalamin"[tw] OR "Palmitate-1-14C"[tw] OR "Rinocusi Vitaminico"[tw] OR "viatmin a"[tw] OR "VitaminoSalmina"[tw] OR
"Vitaminum A"[tw] OR "Viva-Drops"[tw] OR "Vogan"[tw]
8. retino*[tw] OR retinyl palmitate*[tw]
9. beta carotene*[tw] OR betacarotene*[tw] OR carotaben[tw] OR "max caro"[tw] OR maxcaro[tw] OR solatene[tw] OR vetoron[tw]
OR bellacarotin[tw] OR provatene[tw] OR "b-tene"[tw] OR "beta carotin"[tw] OR betatene[tw] OR lurotin[tw] OR solvin[tw] OR "b
Carotene"[tw] OR "B-Caro-T"[tw] OR BETACRTN[tw] OR Caroguard[tw] OR Lumitene[tw] OR "Provitamin A"[tw]
10. (oil*[tw] AND (fish*[tw] OR cod liver*[tw] OR halibut[tw] OR squid[tw] OR krill[tw] OR mackerel[tw] OR menhaden[tw] OR salmon[tw]
OR seal[tw] OR shark liver*[tw] OR seafood[tw]))
11. epa[tw] OR efa[tw] OR maxepa[tw] OR ameu[tw] OR efamed[tw] OR epax[tw] OR feniko[tw] OR himega[tw] OR "k 85"[tw] OR "lachs
550"[tw] OR lipitac[tw] OR olemar[tw] OR optimepa[tw] OR pikasol[tw] OR promega[tw] OR superepa[tw] OR "sea omega"[tw]
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12. omega3[tw] OR "omega 3"[tw] OR n3 fatty acid*[tw] OR n 3 fatty acid*[tw] OR "n3 pufa"[tw] OR "n 3 pufa"[tw] OR n3 polyunsaturated
fatty acid*[tw] OR n 3 polyunsaturated fatty acid*[tw] OR n3 oil*[tw] OR n 3 oil*[tw] OR "bilantin omega"[tw] OR "conchol 36"[tw] OR "eicosa
e"[tw] OR eicosapen[tw] OR epaisdin[tw] OR epanova[tw] OR "omega forte"[tw] OR sakana[tw]
13. docosahex*[tw] OR dhasco[tw] OR dha[tw] OR dpa[tw]
14. eicosapen*[tw] OR timnodonic[tw] OR icosapent*[tw]
15. #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14
16. #6 AND #15
17. #1 AND #16
18. Medline[sb]
19. #17 NOT #18
Appendix 5. LILACS search strategy
(MH:C11.270.684$ OR MH:C11.768.585.658.500$ OR MH:C16.320.290.684$ OR (Retini$ AND Pigment$) OR (Retina$ AND Pigment$) OR
(Retinopath$ AND Pigment$) OR (tapetoretina$ AND degener$) OR (tapetoretina$ AND dystroph$) OR (tapeto retina$ AND degener$) OR
(tapeto retina$ AND dystroph$) OR (rod AND cone AND dystroph$) OR MH:C10.668.829.800.875$ OR MH:C16.320.565.398.500.330.750$
OR MH:C18.452.584.500.875.330.750$ OR MH:C18.452.648.398.500.330.750$ OR "Tangier Disease" OR "Enfermedad de Tangier"
OR "Doença de Tangier") AND ((MH:D02.455.326.271.665.202.495.818$ OR MH:D02.455.426.392.368.367.379.249.700.860$ OR
MH:D02.455.849.131.495.818$ OR MH:D23.767.261.700.860$ OR "vitamin a" OR "aquasol a" OR "vitamin a1" OR "a vitamin"
OR "vit a" OR "A 313" OR "all-trans-retinyl alcohol" OR "Anti-Infective Vitamin" OR "Antixerophthalmic Vitamin" OR "Arovit"
OR "Avibon" OR "Avitol" OR "Axerol" OR "Axerophthol" OR "Axerophtholum" OR "Biosterol" OR "Biovit-A" OR "Chocola A"
OR "Del-VI-A" OR "Ido A 50" OR "Idrurto A" OR "Lard Factor" OR "Ledovit A" OR "Micelle A" OR "Mulsal A Megadosis" OR
"Oleovitamin A" OR "Ophthalamin" OR "Palmitate-1-14C" OR "Rinocusi Vitaminico" OR "viatmin a" OR "VitaminoSalmina" OR
"Vitaminum A" OR "Viva-Drops" OR "Vogan" OR MH:D02.455.326.271.665.202.495$ OR MH:D02.455.426.392.368.367.379.249.700$
OR MH:D02.455.849.131.495$ OR MH:D23.767.261.700$ OR retino$ OR (retinyl palmitate$) OR MH:D02.455.326.271.665.202.123$ OR
MH:D02.455.426.392.368.367.379.249.050$ OR MH:D02.455.849.131.123$ OR MH:D23.767.261.050$ OR (beta caroten$) OR betacarotene*
OR Carotaben OR "Max Caro" OR MaxCaro OR Solatene OR Vetoron OR BellaCarotin OR Provatene OR "b-tene" OR "beta carotin" OR
betatene OR lurotin OR solvin OR MH: D10.627.430$ OR (oil$ AND (fish$ OR "cod liver" OR halibut OR squid OR krill OR mackerel OR
menhaden OR salmon OR seal OR "shark liver" OR seafood)) OR EPA OR EFA OR MaxEPA OR ameu OR efamed OR epax OR feniko OR himega
OR "k 85" OR "lachs 550" OR lipitac OR olemar OR optimepa OR pikasol OR promega OR superepa OR "sea omega" OR "Aceites de Pescado"
OR "Óleos de Peixe" OR MH:D10.212.302.380.410$ OR MH:D10.251.355.337$ OR MH:D10.627.430.450$ OR omega3 OR "omega 3" OR (n3
fatty acid$) OR (n 3 fatty acid$) OR "n3 PUFA" OR "n 3 PUFA" OR (n3 polyunsaturated fatty acid$) OR (n 3 polyunsaturated fatty acid$) OR
(n3 oil$) OR (n 3 oil$) OR "bilantin omega" OR "conchol 36" OR "eicosa e" OR eicosapen OR epaisdin OR epanova OR "omega forte" OR
sakana OR Docosahex$ OR dhasco OR DHA OR DPA OR "Docosa Hexaenoicos"OR eicosapen$ OR timnodonic OR icosapent$))
Appendix 6. metaRegister of Controlled Trials search strategy
(Retinitis Pigmentosa) AND (fish oil OR omga 3 OR docsahexaenoic OR eicosapentaenoic OR vitamin A OR Retino OR carotene)
Appendix 7. ClinicalTrials.gov search strategy
(Retinitis Pigmentosa) AND (Vitamin A OR Retinoids OR beta Carotene OR fish oils OR Omega-3 Fatty Acids)
Appendix 8. WHO ITCRP search strategy
Retinitis Pigmentosa AND Vitamin A OR Retinitis Pigmentosa AND Retinoids OR Retinitis Pigmentosa AND Retinol OR Retinitis Pigmentosa
AND beta Carotene OR Retinitis Pigmentosa AND fish oils OR Retinitis Pigmentosa AND Omega-3 Fatty Acids OR Retinitis Pigmentosa AND
Docosahexaenoic OR Retinitis Pigmentosa AND Eicosapentaenoic
Appendix 9. OpenGrey search strategy
(Retinitis Pigmentosa) AND (Vitamin A OR Retinoids OR beta Carotene OR fish oils OR Omega-3 Fatty Acids)
W H A T ' S   N E W
 
Date Event Description
15 June 2020 New citation required but conclusions
have not changed
Issue 6 2020: One new study (Hoffman 2014) and two new ongo-
ing studies (CTRI/2016/01/006497; NCT00004827) added.
15 June 2020 New search has been performed Issue 6 2020: An updated search yielded results from one new
study. The overall finding that whether giving vitamin A or fish
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Date Event Description
oil, or both to people with retinitis pigmentosa delays the contin-
ued worsening of vision remains uncertain.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the protocol, we stated that we would record visual acuity data at six months. However, when writing the full review, we found that none
of the four included trials reported visual acuity data at six-month intervals.
We stated in the inclusion criteria in the protocol that when both fish oil and vitamin A were included in one group, we would not include a
comparison to vitamin A, which would lead to the exclusion of studies comparing fish oil + vitamin A versus vitamin A. However, our original
Vitamin A and fish oils for preventing the progression of retinitis pigmentosa (Review)









Cochrane Database of Systematic Reviews
intention also included seeking evidence on the eCectiveness of fish oil, therefore we modified this criterion in the review to include such
studies.
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